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INTRODUCTION
In 1990, the Human Genome Project ("HGP") was formed to
decipher and sequence the human genome, to develop new tools to
obtain and analyze genetic data, and to make the information widely
available.' Researchers completed the HGP in 2003 with the genetic
technology and resources developed providing new opportunities for
medical progress. 2 In particular, discoveries about the genetic basis of
illness and the development of genetic testing allowed for earlier
diagnosis and detection of genetic predispositions to disease. 3 These
advances, however, also gave rise to the potential misuse of genetic
information, as revealed by genetic testing, to discriminate against
and stigmatize individuals. 4 More specifically, for example, they
created the opportunity for financially motivated employers to use
genetic information to avoid employing workers likely to take sick
leave, file for workers' compensation, or use health benefits. To fully
protect the public from discrimination and allay any concerns about
the potential for discrimination, in May 2008, President George W.
Bush signed the Genetic Information Nondiscrimination Act 5 ("GINA")
into law. This long-awaited statute paved the way for individuals to
take full advantage of the promise of personalized medicine without
fear of discrimination on the basis of genetic information acquired by
6
employers.
The field of neuroscience is following in the footsteps of
genetics. Large research initiatives, such as the Human Connectome
Project, are currently underway to map the axonal connections of the
human brain and to correlate these circuits with disease and
behavior. 7 Discoveries about the neurological bases of disease have
1.

NAT'L INSTS. OF HEALTH, HANDBOOK: HELP ME UNDERSTAND GENETICS 132-35 (2011)

[hereinafter HANDBOOK], available at httpJ/ghr.nlm.nih.gov/handbook.pdf; Francis S. Collins et
al., New Goals for the U.S. Human Genome Project: 1998-2003, 282 SCIENCE 682, 683-85 (1998).
2.
Genetic Information Nondiscrimination Act of 2008 § 2, Pub. L. No. 110-233, 122 Stat.
at 881-83 (2008) (discussing congressional findings); U.S. Dep't of Energy Office of Sci., Potential
Benefits of Human Genome Project Research, HUMAN GENOME PROJECT INFORMATION,
http://www.ornl.gov/sci/techresources/HumanGenome/projectlbenefits.shtml (last modified Oct.
9, 2009).
3.
See discussion infra Part I.A.
4.
See discussion infra Part I.B.
5.
Genetic Information Nondiscrimination Act of 2008, Pub. L. No. 110-233, 122 Stat. 881
(2008).
6.
See id. § Z 122 Stat. at 881-83 (detailing the congressional findings that led to the
creation of this bill).
7.
Press Release, Nat' Inst. of Mental Health, NIH Launches the Human Connectome
Project
to
Unravel
the
Brain's
Connections
(July
16,
2009),
available at
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already allowed neuroscientists to use patterns of brain structure and
function, as revealed by neuroimaging, to identify neural correlates of
8
disease and predict an individual's predisposition to future disease.
Most importantly, however, this neuro information is susceptible to
the same forms of employer misuse as genetic information. 9 In fact,
Donald Kennedy, neurobiologist and once editor-in-chief of Science,
has already made reference to a "brainome," similar to a "genome":
Far more than our genomes, our brains are us, marking out the special character of our
personal capacities, emotions and convictions. I already don't want my employer or my
insurance company to know my genome. As to my brainome, I don't want anyone to
know it for any purpose whatsoever. It is... my most intimate identity. 10

This Note explores the feasibility of implementing a GINA-like
statute to protect the privacy of individuals' neuro information and to
prevent employment discrimination based on that information. While
GINA applies to both insurance companies and employers, the
motivations and legal issues surrounding insurance discrimination
and employment discrimination vary. Consequently, the analysis of
and approaches to the issues raised in these two contexts should also
vary. This Note solely focuses on employment discrimination and Title
II of GINA as guidance. Future scholarship should inquire about the
need for prohibitions against the use and acquisition of neuro
information in the insurance industry.
This Note begins by reviewing the events leading up to the
enactment of GINA. Part I examines the scientific advancements
stemming from the Human Genome Project, focusing on the predictive
nature of genetic testing. It then discusses the concerns of scientists
and government officials related to the real-world application of these
scientific advancements, more specifically, the concern that employers
would utilize such predictive information to discriminate against
applicants and employees. Part I concludes with a discussion of
Congress's finding regarding the inadequate protection against such
discrimination under existing federal statutes and an overview of the
protections provided for by GINA.
Part II discusses how advancements in neuroimaging present
similar opportunities for discrimination in the workplace. First, it
describes recent advancements in neuroimaging and the massive
http://www.nimh.nih.gov/science-news/2009/nih-launches-the-human-connectome-project-te-

unravel-the-brains-connections.shtml.
8. See discussion infra Part II.A
9. See discussion infra Part II.B.
10. Joan O'C. Hamilton, If They Could Read Your Mind, STANFORD MAG., Jan.-Feb. 2004,
available at http'/alumni.stanford.edu/get/page/magazinelarticle?articleid=36320.
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research initiatives of the Human Brain Project and the Human
Connectome Project. It then explains how neuroimaging technology,
like genetic testing, may be used to identify neurological
predispositions to certain diseases and behavior. Part II concludes by
exploring why, similar to congressional findings in the context of
genetic information, existing federal statutes are insufficient to
protect against employer acquisition and misuse of predictive neuro
information. Part III then examines how neuroscience creates the
opportunity for new forms of discrimination, beyond those considered
in the context of genetics in enacting GINA. It describes recent
advancements
in
neuroenhancements,
specifically
neuropharmaceuticals, and how employers may discriminate on the basis of
the use of such enhancers.
Finally, Part IV proposes a new piece of federal legislation, the
Neuro Information Nondiscrimination Act, to alleviate some of the
emerging problems in the area of neuroscience-based employment
discrimination. To the extent that the discrimination concerns raised
by neuro information are similar to those raised by genetic
information, the genetic-information protections in GINA provide a
framework for developing similar neuro-information protections.
However, to the extent that neuro information raises discrimination
concerns above and beyond those raised by genetic information, such
as in the realm of neuroenhancement, novel approaches are necessary.
I. GENETIC INFORMATION NONDISCRIMINATION ACT OF 2008:
LEGISLATIVE HISTORY, FINDINGS, AND MOTIVATIONS
Representative Louise Slaughter (D-NY) introduced in the
House of Representatives in 1995 the first federal legislation to
prevent genetic discrimination." While some in the healthcare,
research, and policy communities considered the measure forwardlooking, others called it premature, as scientists had just begun
sequencing the human genome.' 2 Nevertheless, anticipating an
imminent explosion in the clinical relevance of genetic information
and the corresponding concern of Americans that employers could use

11. Lauren Elizabeth Nuffort, The Genetic Information Nondiscrimination Act of 2008:
Raisinga Shield to Genetic Discriminationin Employment and Health Insurance, HEALTH LAW.,
June 2009, at 1, 9.
12. Id.
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their genetic information against them, many science professionals
became convinced that reforms were needed as soon as possible.' 3
A. From the Human Genome Project to Genetic Testing: Uncovering the
Human Blueprint
In 1990, an international, collaborative research effort called
the Human Genome Project ("HGP") was formed to map and
understand all of the genes of human beings, or the human genome.14
The National Institutes of Health ("NIH") and the U.S. Department of
Energy directed the HGP. 15 The main goals of the HGP were "to
provide a complete and accurate sequence of the 3 billion DNA base
pairs that make up the human genome" and to locate "all of the
estimated 20,000 to 25,000 human genes."'16 In addition, the HGP
"sought to develop new tools to obtain and analyze the data and to
make this information widely available."'17
Researchers completed the HGP in 2003,18 with the genetic
technology and resources developed profoundly impacting medical
research and promising to revolutionize the wider spectrum of clinical
medicine. 19 Deciphering the sequence of the human genome created
major new opportunities for medical progress, including improved
diagnosis of disease and earlier detection of genetic predispositions to
disease. 20 Dr. Francis Collins, then director of the National Center for
Human Genome Research Institute and now director of the NIH,
described the potential impact the information and tools generated by
the HGP posed for medicine and public health during congressional
testimony before the Senate Health, Education, Labor and Pensions
Committee:
The human genome sequence provides foundational information that now will allow
development of a comprehensive catalog of all of the genome's components,
determination of the function of all human genes, and deciphering of how genes and

13. Id.
14. HANDBOOK, supra note 1, at 132-34.
15. Id. at 134; Collins et al., supra note 1, at 683.
16. HANDBOOK, supra note 1, at 135; see also Collins et al., supra note 1, at 683-85
(discussing how one of the goals of the HGP is to sequence the human genome).
17. HANDBOOK, supra note 1, at 135; see also Collins et al., supra note 1, at 683-85
(explaining the goals of the HGP).
18. HANDBOOK, supra note 1, at 136.
19. U.S. Dep't of Energy Office ofSci, supra note 2.
20. Genetic Information Nondiscrimination Act of 2008 § 2, Pub. L. No. 110-233, 122 Stat.
at 881-83 (2008) (discussing congressional findings); U.S. Dep't of Energy Office of Sci., supra
note 2 (listing some of the major findings).
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proteins work together in pathway and networks. Completion of the human genome
sequence offers a unique opportunity to understand the role of genetic factors in health
and disease and to apply that understanding rapidly to prevention, diagnosis, and
21
treatment.

The most immediate and practical application to come out of
the HGP was genetic testing. 22 A gene is the "basic physical and
functional unit of heredity. '23 Genes, made up of deoxyribonucleic acid
("DNA'), contain the "recipes" for protein creation and "provide the
structural components of all our cells and tissues as well as
specialized enzymes for all essential chemical reactions. ' 24 Every
individual has two copies of each gene, having inherited one copy from
each parent. 25 While most genes are the same in all people, a small
number of genes-less than one percent-differs slightly between
people. 26 Alleles are "forms of the same gene with small differences in
their sequence of DNA bases. '27 Some of this variation in DNA
sequence accounts for physical differences between people and for
28
differences in susceptibility to disease.
Rare sequence variations, called mutations, can cause or vastly
increase the risk of certain diseases by producing "faulty proteins that
function at less-than-normal levels or . . . are completely
nonfunctional. '29 Genetic tests inspect the DNA sample an individual
provides and look for mutated sequences. 30 Genetic tests regarding a
21. NANCY LEE JONES & AMANDA K. SARATA, CONG. RESEARCH SERV., RL30006, GENETIC
INFORMATION: LEGAL ISSUES RELATING To DISCRIMINATION AND PRIVACY 1 (2008) (quoting The
Future of Genomics: Hearing Before the Subcomm. on Health of the H. Comm. on Energy and
Commerce, 108th Cong. 1 (2003) (statement of Francis S. Collins, Director of Human Genome
Research Institute,
National
Institutes
of Health)),
available at httpJ/biotech
.law.lsu.edu/crsRL30006_20080310.pdf.
22. U.S. Dep't of Energy Office of Sci, Gene Testing, HUMAN GENOME PROJECT
INFORMATION,
httpJ/www.ornl.gov/sci/techresources/HumanGenome/medicine/genetest.shtml
(last modified Sept. 17, 2010) (providing a general overview of gene testing).
23. HANDBOOK, supra note 1, at 12.
24. Denise Casey, What Can the New Gene Tests Tell Us?, JUDGES' J., Summer 1997, 14, 14.
25. HANDBOOK, supra note 1, at 12. In a small percentage of clinical pregnancies, an
individual may be born with one chromosome less than the normal number, or monosomy, or
may be born with an additional chromosome, or trisomy. Terry J. Hassold & Patricia A. Jacobs,
Trisomy in Man, 18 ANN. REV. GENETICS 69, 69 (1984).
26. 1000 Genomes, BROAD INST., httpJ/www.broadinstitute.org/science/projects/1000genomes (last visited Oct. 23, 2011); see also HANDBOOK, supra note 1, at 9-11 (confirming this
fact and also providing a general overview of DNA).
27. HANDBOOK, supra note 1, at 12.
28. Casey, supra note 24, at 14-15.
29. Id. at 16.
30. See U.S. Dep't of Energy Office of Sci, supra note 22. ('For some types of gene tests,
researchers design shert pieces of DNA called probes, whose sequences are complementary to the
mutated sequences. These probes will seek their complement among the three billion base pairs
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suspected genetic condition come in two forms: (1) diagnostic testing,
which is "used to confirm or rule out a known or suspected genetic
disorder in a symptomatic individual"; and (2) predictive testing,
which is "offered to asymptomatic individuals," often "with a family
history of a genetic disorder."31 Predictive testing can further be
broken down into two types: (1) presymptomatic-"eventual
development of symptoms is certain when the gene mutation is
present"-and
(2) predispositional-"eventual
development
of
symptoms is likely but not certain when the gene mutation is
32
present."
Through the HGP, scientists have shown that straightforward
inherited errors in genes, capable of presymptomatic testing, account
for a small number of diseases, including Huntington's disease.33 In
contrast, more complex inheritance, capable of only predispositional
testing, increases an individual's risk of developing a large number of
disorders, including cancer, heart disease, and diabetes. 34 Scientists
have also found genetic predispositions to certain behaviors, claiming
to have discovered a "violent gene," 35 a "warrior gene," 36 and a
"monogamy gene." 37 Currently, genetic tests encompass more than

of an individual's genome. If the mutated sequence is present in the patient's genome, the probe
will bind to it and flag the mutation. Another type of DNA testing involves comparing the
sequence of DNA bases in a patient's gene to a normal version of the gene.").
31. Natl Ctr. for Biotechnology Info., Uses of Genetic Testing, GENETFSTS, httpJ/www.ncbi
.nlm.nih.gov/projectslGeneTestslstatic/concepts/primer/primerusesof.shtml
(last updated Mar.
19, 2004) [hereinafter GENETESTS].
32. Id.
33. DEP'T OF LABOR ET AL., GENETIC INFORMATION AND THE WORKPIACE (1998), available at
http://www.genome.gov/10001732.
34. Id.
35. See Niall Firth, The 'Violent' Gene: Genetic Mutation Found Only in FinnishMen that
Makes Them Fight, DAILY MAIL, Dec. 23, 2010, http://www.dailymail.co.uklsciencetecbarticle1341100/The-violent-gene-Genetic-mutation-Finnish-men-makes-fight.html (discussing a genetic
mutation that makes Finnish men more impulsive and aggressive, especially when drunk); see
also Avshalom Caspi et al., Role of Genotype in the Cycle of Violence in Maltreated Children, 297
SCIENCE 851, 853 (2002) (suggesting that children with high MAOA gene expression were less
likely to be violent).
36. See Warrior Gene' Linked to Gang Membership, Weapon Use, SCIENCEDAILY, June 5,
2009, http://www.sciencedaily.com /releasest2009/06/090605123237.htm (noting that boys who
carry a certain gene are more likely to join gangs and engage in violence).
37. See Priya Shetty, Monogamy Gene Found in People, NEWSCIENTIST (Sept. 1, 2001, 10:00
PM),
httpJ/www.newscientist.com/article/dn14641-monogamy-gene-found-in-people.html
(describing the discovery of a certain gene that may determine how well you will bond with a
partner).
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two-thousand conditions, 38 with many of these tests available in
39
clinics and some even offered directly to consumers.
B. Imperfect Predictionand Employer Misuse
The reports and testimony prepared in the context of the
congressional debates surrounding GINA recognized that these
scientific advances in genetics, while promising, were not without
potential problems. The knowledge and tools stemming from the HGP
provided new opportunities for medical progress.4 0 Most notably,
discoveries about the genetic basis of illness allowed for earlier
detection of illness and for the development of more effective therapies
to treat disease.4 1 However, these advances also gave rise to the
potential misuse of genetic information to discriminate against or to
stigmatize individuals in the workplace.4 2 For instance, an employer
may choose to penalize prospective or current employees merely
because they have a higher probability of contracting a certain disease
or disorder in the future.
The ethical, social, and legal implications of genetic research
have long been the subject of significant scrutiny. From its inception,
the HGP devoted a portion of its funding to conducting research on the
Ethical, Legal, and Social Implications ("ELSr') of genomics and "to
develop[ing] recommendations to address the research, health and
public policy implications of the rapidly accumulating genetic
knowledge and technologies." 4 3 ELSI realized that while the HGP

38. GENETESTS, supra note 31 (reporting that as of February 9, 2012, there were 2,539
conditions that were able to be genetically tested for).
39. Kathy Hudson et al., Keeping Pace with the Times: The Genetic Information
NondiscriminationAct of 2008, 358 NEW ENGLAND J. MED. 2661, 2661 (2008).
40. Genetic Information Nondiscrimination Act of 2008 § 2, Pub. L. No. 110-233, 122 Stat.
881, 881-82 (2008) (discussing congressional findings).
41. Id.
42. Id.
43. Genetic Information in the Workplace: HearingBefore the S. Comm. on Health, Educ.,
Labor & Pensions, 106th Cong. (2000) (statement of Francis S. Collins, Director of Human
Genome Research Institute, National Institutes of Health) [hereinafter Workplace Hearings],
available at http://www.genome.gov/10001380; see also U.S. Dep't of Energy Office of Sci.,
Ethical, Legal and Social Issues, HUMAN GENOME PROJECT INFORMATION, http://www.ornl
.gov/sci/techresources/Human.Genome/elsilelsi.shtml (last updated Aug. 24, 2011) (discussing
how the Human Genome Project has consistently dedicated three to five percent of its budget to
ELSI activities). As of 2006, this amounted to over $150 million, "leading to hundreds of articles,
books, conferences, and other research and educational activities on the ethical, legal, and social
implications of genetics." Henry T. Greely, Neuroethics and ELSI: Similaritiesand Differences, 7
MINN. J.L SCI. & TECH., 599, 604 (2006).
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opened major new opportunities for medical progress, the predictive
nature of genetic testing was not without unique legal and ethical
implications.4 4 The "proper uses of such predictive technologies," as
well as "the propriety of various users," such as employers, garnered
45 Most
much of the attention of ELSI throughout the years.
importantly, "[e]arly research and subsequent policy deliberations
conducted by the ELSI program ... led to a series of recommendations
for safeguarding the privacy and fair use of genetic information in ...
the workplace." 46 Those recommendations, published in Science
magazine in the mid-1990s, 47 served as a model for much of the
48
modern workplace legislation in this context.
The congressional debates leading up to the enactment of
GINA echoed the concerns raised by ELSI regarding the potential for
employers to discriminate on the basis of genetic predisposition. An
intra-agency report described how the science behind the use of
genetic testing to predict future conditions was imperfect:
Genetic technologies, such as simple DNA tests, increasingly are becoming available to
identify people who might have an increased likelihood of developing a disorder. The
majority of diseases Americans encounter, however, do not result solely from genetic
predisposition but from the interaction of genes with environmental factors, including
occupation, diet, and lifestyle. Consequently, genetic tests alone cannot predict with
certainty whether a person with a particular genetic error will in fact develop a
49
disease.

During congressional testimony before the Senate Health,
Education, Labor and Pensions Committee, Dr. Francis Collins
expressed concern about the misuse of genetic information, stating
that, "while genetic information and genetic technology hold great
promise for improving human health, they can also be used in ways
that are fundamentally unjust," specifically "[g]enetic information can
be used as the basis for insidious discrimination." 50 In particular, Paul
Steven Miller, commissioner of the U.S. Equal Employment

44.
45.
46.
Genome

Collins et al., supranote 1, at 687-88.
Greely, supra note 43, at 611.
Workplace Hearings,supra note 43 (statement of Francis S. Collins, Director of Human
Research Institute, National Institutes of Health).

47. Karen Rothenberg et al., Genetic Information and the Workplace: Legislative
Approaches and Policy Challenges, 275 SCIENCE 1755, 1756-57 (1997) (listing five
recommendations for state and federal policymakers).
48. Workplace Hearings, supra note 43 (statement of Francis S. Collins, Director of Human
Genome Research Institute, National Institutes of Health).
49.

DEP T OF LABOR ETAL., supranote 33.

50. Workplace Hearings, supra note 43 (statement of Francis S. Collins, Director of Human
Genome Research Institute, National Institutes of Health).
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Opportunity Commission ("EEOC'), expressed to the Committee that
the "surge in genetic research and technology, fueled in large part by
the Human Genome Project," has resulted in the "risk that employers
will misinterpret and misuse genetic test results to weed out persons
according to their perceived health risks based on genetic
51
information."
One report described the cost-cutting motivation of employers
to use such imperfect predictive tests, stating that "[b]ased on genetic
information, employers may try to avoid hiring workers who they
believe are likely to take sick leave, resign, or retire early for health
reasons (creating extra costs in recruiting and training new staff), file
52
for workers' compensation, or use health care benefits excessively."
Concern with respect to genetic information's imperfect predictive
ability was not limited to the individual's health. Although not as
extensively discussed by ELSI or Congress, there was also concern
over employers using genetic information to predict behavior or
personality. 53 For example, Congress feared that employers might test
potential employees to determine who is more likely to be diligent or
loyal based on their genetic predispositions. Overall, although it may
be economically efficient from the perspective of the employer, there
was a concern that making employment decisions on the basis of
predispositions conflicted with society's merit-based belief in judging
individuals on their abilities alone. President Bush, in a 2001 radio
address to the nation, stated that such utilization of "medical
speculation" by employers is "unjustified."54 Denying employment to
an individual based on a predisposition "violates our country's belief in
equal treatment and individual merit" 55 and is inconsistent with the

51. Workplace Hearings, supra note 43 (statement of Commissioner Paul Steven Miller,
EEOC) (emphasis added), available at http://www.genome.gov/10001390.
52. DEP'T OF LABOR ETAL., supranote 33.
53. See Thomas F. Wieder, Privacy Protection is Needed for DNA, 2002 L. REV. MICH. ST. U.
DETROIT C. L. 927, 928-29 (discussing the eugenics movement in which individuals that were
"feeble minded," "criminalistic," and "inebriate" were considered to be in a socially inadequate
class, subject to sterilization due to their undesired behavioral characteristics); see also
Symposium, The Human Genome Project, DNA Science and the Law: The American Legal
System's Response to Breakthroughs in Genetic Science, 51 AM. U. L. REV. 451, 464-65 (2002)
(discussing potential employee discrimination on the basis of genetic markers corresponding to
cognitive skill)..
54. President George W. Bush, Radio Address by the President to the Nation (June 23,
2001), available at httpJ/www.genome.gov/11510235.
55. Id.
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American principle that "people should be judged based upon their
56
abilities, and not based upon fears; myths or stereotypes."
C. InadequateExisting Federal Statutory Protections
From the time of GINA's inception to its enactment, a "hotly
57
contested" debate ensued in Congress over the need for reform.
While the debate initially ignited in the 104th Congress, the
arguments and views supporting and opposing the legislation
remained consistent for the most part from one legislative session to
the next. 58 Opponents of federal legislation, including members of the
insurance industry and employers represented by the Genetic
Information Nondiscrimination in Employment ("GINE ' ) Coalition,
extensively argued that other bodies of federal law were sufficient to
deal with any misuse of genetic information by employers. 59 These
opponents cited the Americans with Disabilities Act ("ADA'), 60 Title
VII of the Civil Rights Act of 1963 ("Title VII"),61 and Executive Order
13,145 To Prohibit Discrimination in Federal Employment Based on
Genetic Information ("Executive Order 13,145")62 to support their
position that the passage of GINA would only create confusion and
unnecessary costs. 63 Proponents of federal nondiscrimination
legislation countered that "current laws [were] not clear on
protection." Further, since the existing federal laws had not been

56. Workplace Hearings, supra note 43 (statement of Commissioner Paul Steven Miller,
EEOC). A joint report by the Department of Labor, the Department of Health and Human
Services, the EEOC, and the Department of Justice similarly found that "genetic predisposition
or conditions can lead to workplace discrimination, even in cases where workers are healthy and
unlikely to develop disease or where the genetic condition has no effect on the ability to perform
work." DEP'T OF LABOR ET AL, supra note 33.

57.

Nuffort, supra note 11, at 9.

58. Id. at 9-10.
59. Id. at 10-11.
60. Americans with Disabilities Act (ADA) of 1990, Pub. L. No. 101-336, 104 Stat. 327
(1990) (codified as amended in scattered sections of 29 U.S.C., 42 U.S.C., & 47 U.S.C.).
61. 42 U.S.C. § 2000 (2006).
62. 65 Fed. Reg. 6877 (Feb. 10, 2000).
63. JONES & SARATA, supra note 21, at 3 (quoting Genetic Non-Discrimination:Examining
the Implications for Workers and Employers: Hearing Before the Subcomm. on EmployerEmployee Relations of the House Comm. on Educ. and the Workforce, 108th Cong. 37 (2004)
(testimony of Lawrence Lorber, on behalf of the U.S. Chamber of Commerce)); Nuffort, supra
note 11, at 4, 10-11.
64. Nuffort, supra note 11, at 4.
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properly tested in court, the proponents argued that the scope of their
protection was "highly speculative."65
The insufficient protections afforded genetic information by
Title VII and Executive Order 13,145 were easily discernible. Title VII
is limited to prohibiting employment discrimination on the basis of
race, color, religion, sex, and national origin. 66 Therefore, under Title
VII, "employees can prevail on a claim [only] if they establish that the
employer singled out a specific protected class for genetic testing."67
Executive Order 13,145 narrowly prohibits the federal government
from taking adverse employment actions based on an employee's
"protected genetic information" and therefore did not protect the
majority of Americans who were not employed or applying for
employment with the federal government. 68 However, more time and
effort were required to identify the gaps and uncertainties of
protection under the ADA before Congress ultimately concluded that
new legislation was necessary.
Reports and hearings conducted during the congressional
debate revealed that the currently existing federal framework
provided under the ADA did not protect workers from requirements or
requests to provide genetic information to their employers or from the
employer purchasing an employee's genetic information from a data
bank.6 9 Under the statute, an employer may not make medical
inquiries about an applicant before extending a conditional offer of
employment.70 However, "once a conditional offer of employment has
been extended, but before the individual begins work, the employer
may obtain extensive medical information about the applicant,
including genetic information." 7 1
65. Id.
66. 42 U.S.C. § 2000e-2(a); Joanne Barken, Note, Judging GINA Does the Genetic
Information NondiscriminatonAct of 2008 Offer Adequate Protection?, 75 BROOK. L REV. 545,
560-61 (2009).
67. Barken, supra note 66, at 560-61; see also Christine Formas Norris, Note, The Genetic
Information NondiscriminationAct of 2008: History, Successes, and Future Considerations, 7 U.
MD. LJ. RACE RELIGION GENDER & CLASS 192, 206 (2007) (discussing the inadequate legal
protections provided by Title VII in the realm of employment discrimination on the basis of
genetic information).
68. Barken, supra note 66, at 561-63.
69. DEVT OF LABOR ET AL, supra note 33; see also Workplace Hearings, supra note 43
(statement of Commissioner Paul Steven Miller, EEOC) ("[Tlhe ADA does not protect workers
from requirements or requests to provide genetic information to their employers.').
70. 42 U.S.C. § 12112(d)(2)(A) (2006); DEP'T OF LABOR ETAL., supra note 33.
71. DEPT OF LABOR ET AL., supra note 33; see also Norman-Bloodsaw v. Lawrence Berkeley
Lab., 135 F.3d 1260, 1273 (9th Cir. 1998) (finding no ADA violation when genetic tests were
administered after the job was offered and prior to employment).
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For example, in Norman-Bloodsaw v. Lawrence Berkeley
Laboratory, the Court of Appeals for the Ninth Circuit ruled that an
employer's practice of testing for the sickle-cell trait, among other
things, did not constitute a violation of the ADA. 72 The complaint
alleged that the defendants violated the ADA by requiring such
genetic testing because the required testing constituted medical
examinations and medical inquiries that were "neither job-related nor
consistent with business necessity." 73 The court upheld the dismissal
of the ADA claims, finding that since the medical inquiries were
conducted as part of an employment entrance examination, they "need
not be concerned solely with the individual's 'ability to perform jobrelated functions' " nor must they be "job-related or consistent with
business necessity." 74 Thus, considering the seemingly limitless scope
of "preplacement examinations" 75 allowed under the ADA, during this
time, an employer could go as far as "to obtain and store genetic
samples of job applicants, require genetic screening as a condition of
employment, or purchase genetic information about applicants from a
76
genetic information data bank."
Furthermore, proponents of GINA showed that the ADA was
insufficient to prohibit employers, once they are in possession of
77
genetic information, from misusing the information to discriminate.
Title I of the ADA, which protects individuals seeking work or working
in the private sector from discrimination on the basis of disability,
makes no explicit mention of genetic information. Rather, the ADA
contains broad language prohibiting discrimination against a
"qualified individual with a disability" in hiring, promotion, discharge,
compensation, and other terms and conditions of employment. 78 The
ADA defines an individual with a disability as a person with "(A) a
physical or mental impairment that substantially limits one or more of
the major life activities of such individual; (B) a record of such an

72. Norman-Bloodsaw, 135 F.3d at 1273-74.
73. Id. at 1273.
74. Id. (citing 42 U.S.C. § 12112(d)(2), (d)(4) in part).
75. Id. at 1264.
76. DEP'T OF LABOR ET AL., supra note 33. In addition, under the ADA, "once the applicant
is hired the employer may request medical information that is job related and consistent with
business necessity." Id. This may be allowed, even though genetic test information alone is not a
reliable basis for concluding that someone has an actual disease. Id
77. DEP't OF LABOR ETAL., supra note 33.
78. 42 U.S.C. §§ 12,111-17.
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impairment; or (C) being regarded as having such an impairment." 79
While the ADA clearly protects an employee who develops a
genetically related illness when the illness begins to limit a major life
activity substantially, it fails to address whether an employee's
genetic information, which indicates the likelihood of developing a
future disease, can constitute a bona fide disability.8 0
In 1995, the EEOC stated its position that the ADA "regarded
as" prong protects individuals with genetic markers for illness,
8
disease, or other disorders from discrimination in employment. '
However, as several GINA-related reports and hearings emphasized,
EEOC policy guidance does not have the same force of law as a federal
statute.8 2 In fact, courts in the past have disagreed with the EEOC's
regulations under the ADA. 8 3 Therefore, given this limited and
uncertain protection and "in light of the accelerated pace of genetic
discovery, the uniqueness of genetic information, [and] the great
potential for discrimination," 84 Congress concluded that additional
legislation was necessary to ensure adequate protections against both
85
obtainment and unfair use of genetic information by employers.

79. § 12102(1); see 42 U.S.C.A. § 12102(3)(A) (West 2012) ("An individual meets the
requirement of 'being regarded as having such an impairment' if the individual establishes that
he or she has been subjected to an action prohibited under this Act because of an actual or
perceived physical or mental impairment whether or not the impairment limits or is perceived to
limit a major life activity.").
80. DEP'T OF LABOR ET AL., supra note 33; Mark S. Dichter & Sarah E. Sutor, The New
Genetic Age: Do Our Genes Make Us Disabled Individuals Under the American with Disabilities
Act?, 42 VILL. L. REV. 613, 620 (1997).
81. U.S. EQUAL EMPIr OPPORTUNITY COMM'N, COMPLIANCE MANUAL § 902 (1995); see also
Press Release, EEOC, EEOC Settles ADA Suit Against BNSF for Genetic Bias (Apr. 18, 2001)
available at
http://www.eeoc.gov/eeoc/newsroomirelease4-18-O1.cfm
(quoting
EEOC
Commissioner Paul Steven Miller as saying, "Employers must understand that basing
employment decisions on genetic testing is barred under the ADA's 'regarded as' prong, as stated
in EEOC's 1995 policy guidance on the definition of the term 'disability.' ").
82. DEP'T OF LABOR ET AL., supra note 33; Workplace Hearings,supra note 43 (statement of
Commissioner Paul Steven Miller, EEOC).
83. See Sutton v. United Airlines, 527 U.S. 471, 479-80 (1999) (finding that the EEOC did
not possess agency regulation-writing authority with respect to the ADA's definitions).
84. DEP'T OF LABOR ETAL., supranote 33.
85. See Genetic Information Nondiscrimination Act of 2008 § 2(5), Pub. L. No. 110-233, 122
Stat. 881, 882 (2008) ("Congress has collected substantial evidence that the American public and
the medical community find the existing patchwork of . .. Federal laws to be confusing and
inadequate to protect them from discrimination.').
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D. Text of GINA
After a thirteen-year legislative battle, President George W.
Bush signed the Genetic Information Nondiscrimination Act of 2008
into law. In the time between GINA's inception and its enactment, the
field of genomics had grown exponentially.8 6 Congress passed the bill,
intending for GINA to replace the "existing patchwork of ... Federal
laws" and "to fully protect the public from discrimination and allay
their concerns about the potential for discrimination, thereby allowing
individuals to take advantage of genetic testing, technologies,
87
research, and new therapies."
GINA, referred to by Senator Edward Kennedy as "the first
major new civil rights bill of the new century,"8 8 is a complex bill that
prohibits employment and insurance discrimination based on genetic
information. Title I bars group health plans and health insurers from
conditioning the insurance of healthy individuals solely on genetic
information.8 9 Title II parallels language from Title VII of the Civil
Rights Act of 1964 and applies to employers, employment agencies,
labor organizations, and employee and apprenticeship training
programs. 90 It prohibits such entities from requesting or requiring
genetic information, from discriminating on the basis of genetic
information, and from disclosing an employee's genetic information. 91
First, Title II makes it an "unlawful employment practice" for
an employer, employment agency, labor organization, or training
program to request, require, or purchase the genetic information of an
employee or of a family member of the employee. 92 The statute carves
out six exceptions to this prohibition for employers and five
exceptions-which effectively mirror employer exceptions one through
93
five-for other nonemployer Title II entities.

86. See discussion supra Part I.A.
87. Genetic Information Nondiscrimination Act of 2008 § 2(5), 122 Stat. at 882
(congressional findings).
88. Hudson et al., supra note 39, at 2662.
89. Genetic Information Nondiscrimination Act §§ 101-106, 122 Stat. at 883-905. This Note
focuses on employment discrimination on the basis of neuro information and therefore will not
discuss Title I of GINA in depth.
90. §§ 202-206, 122 Stat. at 905-14.
91. Id.
92. §§ 202(b), 203(b), 204(b), 205(b), 122 Stat. at 907, 909, 910, 912.
93. §§ 202(b), 203(b), 204(b), 205(b), 122 Stat. at 907, 909, 910, 912. These employer
exceptions include: (1) where the employer inadvertently requires or requests genetic
information; (2) where the genetic information is provided to the employer as part of an
employer-administered wellness program, offering health and genetic services; (3) where the
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Second, Title II makes it unlawful for employers and employer
organizations to discriminate on the basis of genetic information.
GINA forbids an employer from discharging or refusing or failing to
hire an employee because of genetic information.94 It also makes it
unlawful for an employer to discriminate against any employee with
"respect to compensation, terms, conditions, or privileges
of
employment" because of genetic information. 95 Similarly, GINA
forbids an employment agency from refusing or failing to refer for
employment any individual because of genetic information; 96 forbids a
labor organization from excluding or expelling from membership any
individual because of genetic information; 97 and forbids training
programs from discriminating against any individual because of
genetic information with respect to admission to or employment in any
program to provide apprenticeship or other training. 98 GINA also
makes it unlawful for Title II entities to "limit, segregate, or classify"
an employee in any way that would deprive him of employment
opportunities or would adversely affect his status as an employee on
the basis of genetic information. 99 Further, such nonemployer entities
are forbidden from causing or attempting to cause an employer to
discriminate against an individual on the basis of genetic
information.1 00
Finally, Title II of GINA provides for the confidential
treatment of genetic information if an employer or employer entity
comes into possession of such information about an employee or
member. 10 1 The statute requires that the entity maintain genetic
information on separate forms and in separate medical files and treat
the information as a confidential medical record. 0 2 GINA makes it

employer requires or requests genetic information to comply with certification provisions of the
Family Medical Leave Act of 1993; (4) where the employer purchases genetic information that is
commercially and publicly available; (5) where the employer requests or requires genetic
information to monitor the biological effects of toxic substances in the workplace; and (6) where
the employer conducts DNA analysis for law enforcement purposes as a forensics laboratory. §
202(b), 122 Stat. at 907.
94. § 202(a)(1), 122 Stat. at 907.
95. Id.
96. § 203(a)(1), 122 Stat. at 908.
97. § 204(a)(1), 122 Stat. at 910.
98. § 205(a)(1), 122 Stat. at 911.
99. §§ 202(a)(2), 203(a)(2), 204(a)(2), 205(a)(2), 122 Stat. at 907, 908-09, 910, 912.
100. §§ 203(a)(3), 204(a)(3), 205(a)(3), 122 Stat. at 909, 910, 912.
101. § 206, 122 Stat. at 913-14.
102. § 206(a), 122 Stat. at 913.
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unlawful for a Title II entity to disclose genetic information concerning
10 3
an employee or member, except in a few limited circumstances.
Legal scholars have been quick to point out the shortcomings of
GINA. 1°4 However, despite its imperfection, most agree that the
statute is an "important recognition of the power of genetic medicine,
the injustice of discrimination based on genetic factors beyond
individual control, and the importance of health care and employment
to each individual."1 05 GINA surely is not an end to the problems of
genetic discrimination, but it ensures that conversation and debate
continue to occur in the field so that present and future legislation can
evolve on pace with the spectacular advancements in genetic science.
II. THE POTENTIAL FOR PREDICTIVE NEUROIMAGING-BASED
DISCRIMINATION

Legal scholars and scientists agree that the world is in the
middle of a "revolution in neuroscience."' 10 6 Compared to thirty years
ago, scientists now know far more about the structure and function of
the human brain.10 7 In the past decade alone, some claim that
neuroscience has entered "a period of extraordinary, perhaps
unprecedented promise."' 0 8 This revolution in neuroscience, like most
science revolutions, was made possible by a revolution in tools103. § 206(b), 122 Stat. at 913-14. A Title II entity may disclose genetic information: (1) to
the employee or labor organization member at the written request of the employee or labor
organization member; (2) to an occupational or health researcher in compliance with federal
regulations; (3) to court officials in response to a court order; (4) to government officials
investigating compliance with Title II of GINA; (5) to the extent such disclosure is made in
connection with the employee's compliance with the Family Medical Leave Act of 1993; and (6) to
a federal, state, or local public health agency. Id.
104. See Cheryl Erwin, Legal Update: Living with Genetic Information Nondiscrimination
Act, 10 GENETICS MED. 869, 871-72 (2008) (discussing how GINA still provides a number of legal
ways for employers to access employee's genetic information and how GINA fails to address the
coercive effects that employers may exert on applicants to provide their genetic information);
Norris, supra note 67, at 193 (discussing how GINA does not regulate genetics research that can
reinforce racial, ethnic, and other stereotypes); Mark A. Rothstein, Is GINA Worth the Wait?, 36
J.L. MED. & ETHICS 174, 174 (2008) (describing GINA as being "fatally flawed" due to its failure
to adequately protect the privacy of employee health information).
105. Erwin, supra note 104, at 872; see also Paul R. Billings, Beyond GINA, 14 NATURE MED.
806, 806 (2008) ("GINA is . . . a sentinel step in the adaptation of our society to deeper
understanding of our personal genetics and as a moment of restatement of our most deeply held
values.'); Rothstein, supra note 104, at 177 (stating that GINA is valuable for its "symbolism" as
declaring a national policy against discrimination on the basis of genetic information).
106. Henry T. Greely, Law and the Revolution of Neuroscience: An Early Look in the Field,
42 AKRON L. REV. 687, 688 (2009).
107. Id.
108. Hamilton, supra note 10.
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imaging, statistical, and databank tools. 10 9 The combination of
advancements in these powerful, emerging tools has made it possible
to use neuroimaging, similarly to genetic information, to predict an
individual's future propensity for disease or behavior. Neuroimaging
studies can look at different patterns of brain images taken under
varying circumstances and then can correlate these patterns with
different behaviors or conditions. 110 Therefore, while genetics affords
insights into an individual's future health conditions and behavior by
developing the association between a person's genes and bodily states,
neuroscience focuses on brain structure and functioning that can
indicate normal and abnormal patterns and correlates such patterns
with present or future health and behavior.
A. From the Human Brain Project to PredictiveNeuroimaging:
Uncovering the Human Brainprint
Advancements in neuroimaging have made it possible, for the
first time, to look inside a living, healthy human brain noninvasively
and to see its detailed structure and functioning."' These
advancements also allow neuroscientists to begin to correlate the
physical states of the brain, revealed by these tools, with the states of
the mind that certain activities produce. 112 Neuroimaging may reveal
the structure of the living brain, through technologies such as
computer-assisted tomography ("CAT') scans or magnetic resonance
imaging ("MRI"), or it may show the function of different parts of the
living brain, through positron emission tomography ("PET') scans,
single photon emission computed tomography ("SPECT') scans,
electroencephalography ("EEG"), or functional magnetic resonance
imaging ("fMRI").113
Functional magnetic resonance imaging is "one of the most
exciting windows into the black box" of the brain." 4 An fMRI scan
utilizes the tendency of nerve cells to metabolize oxygen in the blood

109. Greely, supra note 106, at 688.

110. Id.
111. Id.
112. Id.
113. See Committee on Science and Law, Are Your Thoughts Your Own?: 'Neuroprivacy"and
the Legal Implications of Brain Imaging, 60 RECORD 407, 410-11 (2005) (discussing the
underlying technology and uses of CAT, PET, SPECT, MRI, fMRI, and EEG scanning).
114. JONATHAN D. MORENO, MIND WARS: BRAIN RESEARCH AND NATIONAL DEFENSE 98
(2006).
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surrounding the cells when they are activated. 115 The scan then
records the difference between oxygenated and nonoxygenated blood
cells so that more active neurons can be identified and distinguished
from less active ones. 116 By using this scanning ability while an
experimental subject performs or undergoes a specific task or
experience, scientists can correlate activated neural systems and
mental activity. 117
Recently, several major information-gathering initiatives in
neuroscience are attempting to use these advancements in
neuroimaging of brain structure and function to show propensity for
developing certain diseases and mental abnormalities. One of these
initiatives is the Human Brain Project, which commenced around the
same time as the HGP. l l8 From 1993 through 2005, the Human Brain
Project awarded over $100 million in grants toward achieving its goal
of "stimulat[ing] the development of advanced technologies for sharing
data on the brain through digital databases of brain images and
mapping." 119 One of its greatest accomplishments was the creation of
the fMRI Data Center, a public repository of neuroimaging
information. 120 The neuroscientists that spearheaded the fiVIRI Data
Center stated that they hoped it would spur discoveries in
neuroscience the same way that GenBank, a public database of gene
sequences that operated alongside the HGP,121 had spurred
discoveries in genetics. 122 The fMRI Data Center makes raw data from
neuroimaging studies available to researchers and organizes the data
so that interesting features can be extracted from it systematically. 123

115. Id.
116. Id.
117. Id. at 98-99.
118. Press Release, Nat'l Inst. of Mental Health, Making Sense of the Brain's Mind Boggling
Complexity (Apr. 16, 2004), available at httpJ/www.nimh.nih.gov/science-news/2004/makingsense -of-the -brains-mind-bo ggling-complexity.shtml.
119. Kurt Samson, Will the Demise of the NIH Human Brain Iroject Hurt the Growth of
Neuroinformatics?,NEUROLOGY TODAY, Mar. 7, 2006, at 34, 34-35.
120. Id. at 35; GeneralInformation,THE FMRI DATA CTR., http://www.fmridc.org/f/fmridc/
aboutus/index.html (last visited Oct. 23, 2011).
121. See Press Release, Natl Inst. of Health, GenBank Celebrates 25 Years of Service with
Two-Day Conference (Apr. 3, 2008), available at http://www.nih.gov/news/healtl/apr2O08/nlm03.htm (discussing how the Human Genome Project would send GenBank sequence data as it
was generated).
122. Open Your Mind, THE ECONOMIST, May 23, 2002, http://www.economist.comnode/
1143317.
123. Id.; General Information, THE FMRI DATA CTR., httpJ/www.fmridc.org/f/fmridcaboutust
index.html (last visited Oct. 23, 2011).
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In 2009, utilizing advancements in neuroimaging and in
neuroinformatics generated by the Human Brain Project, 124 NIH
launched the Human Connectome Project. 25 Just as the HGP mapped
the entire human genome, the Human Connectome Project aims to
gain insight into how brain connections underlie brain function by
systematically mapping the axonal connections of the entire, living
human brain. 126 By combining powerful, emerging technologies, the
Human Connectome Project will map the brain's circuits and then
attempt to link these circuits to the full spectrum of brain function in
health and disease. 127 Connectivity patterns revealed by imaging of
brain structure and function will be combined with behavioral testing
and genotyping in an effort to determine how small changes in brain
8
connectivity relate to individual differences in behavior and disease. 12
Additionally, this past year, a team of researchers published
the first analysis from a related endeavor, called the 1000 Functional
Connectomes Project, that illustrated the success that projects such as
the Human Connectome Project may yield. 129 The team, led by
Michael Milham, a neuroscientist at New York University Childhood
Study Center, analyzed a collection of fMRI data sets donated by
researchers from thirty-five centers around the world. 130 The sets
consisted of data from more than fourteen-hundred subjects who
underwent fMRI scans to assess their brain activity when their minds
were at rest.' 3' The study revealed that resting-state fiVIRI datapreviously thought by neuroscientists to be only white noise-can be
pooled reliably to unveil an underlying "universal architecture of

124. In announcing that it would not accept any more grant applications in 2005, essentially
ending the Human Brain Project initiative, Dr. Michael Huerta, director of the Office of
Interdisciplinary Research and Scientific Technology at the National Institute of Mental Health,
said that the project had been a success and that neuroinformatics can now be mainstreamed
into other research at NIH. Samson, supra note 119, at 35.
125. Press Release, Nat'l Inst. of Mental Health, NIH Launches the Human Connectome
Project
to
Unravel
the
Brain's
Connections
(July
16,
2009),
available at
http://www.nimh.nih.gov/science-news/2009/nih-launches-the-human-connectome-project-tounravel-the-brains-connections. shtml.
126. Id.
127. Id.
128. Christophe Lenglet et al., Decipheringthe Human-BrainConnectome, SPIE NEWSROOM
(Dec. 7, 2010), http://spie.org/x43323.xml?pf--true&ArticleID-x43323.
129. Elie Dolgin, This is Your Brain Online: The FunctionalConnectomes Project, 16 NATURE
MED., 351, 351 (2010).
130. Michael P. Milham et al., Toward Discovery Science of Human Brain Function, 107
PROC. NAT'L ACAD. SC., 4734, 4734 (2010).
131. Id.
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activity connections within the brain." 132 Even more exciting, while
the human functional connectome overall has a common architecture,
"each individual's functional connectome exhibits unique features,
with stable, meaningful interindividual differences in connectivity
patterns and strengths."'133 This suggests that, just as there is
predictable genetic variation in different alleles at particular loci in
the genome, there are also consistent loci of variability between
individuals in their functional connectomes.
The discoveries made by the 1000 Functional Connectomes
Project and the future discoveries to come from the Human
Connectome Project will allow for "systematic explorations of healthy
and diseased brains to discover hitherto unknown underlying
differences."'134 This moves the field in the direction of being able to
objectively test and predict serious mental illness, neurological
disorders, and personality traits on a large scale. 135 Eventually, "data
from myriads of neuroscientific studies may be integrated in
databases, similar to gene and protein sequence databases," to create
a "human brainome 136 or "brain atlas" that will provide "a probability
distribution for different cerebral characteristics and some indication
of 'normal' brain activity [and structure] ."137 Then, just as with genetic
tests, an individual's brain could be scanned and compared to normal
brain activity and structure. Any differences between the scan and
normality could be thought of as "brain mutations," similar to gene

132. Dolgin, supra note 129, at 351; see also Milham et al., supra note 130, at 4735-38
(discussing the feasibility of pooling resting state fMRI datasets across research centers).
133. Milham et al., supra note 130, at 4734-36 (finding that "centers demonstrated a high
degree of agreement on which connections are characterized by relative variance or invariance').
134. Dolgin, supra note 129, at 351 (discussing how large databases of brain images, such as
the 1000 Functional Connectomes resource, can serve as a reference of activity patterns within
the human brain, allowing for "systematic explorations of health and diseased brains to discover
hitherto unknown underlying differences"); see also Huda Akil, Challengesand Opportunities in
Mining Neuroscience Data, 331 SCIENCE 708, 709-10 (2011) (discussing how the Human
Connectome Project will provide data mining options to reveal connectivity differences between
subpopulations that are selected by different phenotypes); Tal Yarkoni, Cognitive Neuroscience
2.0: Building a Cumulative Science of Human Brain Function, 14 TRENDS COGNITIVE ScI. 489,
492 (2010) (discussing how the 1000 Functional Connectomes Project and Human Connectome
Project will provide "immense amounts of information on brain connectivity?').
135. Dolgin, supra note 129, at 351.
136. Committee on Science and Law, supra note 113, at 428 (discussing how reference has
been made to a "brainome" similar to a "genome").
137. Id. at 428, 432; see also Yarkoni, supra note 134, at 494 box 3 (discussing as a possible
future development, 'Tully automated quantitative mapping between cognitive and neural states"
whereby "[riesearchers would upload observed activation maps to a database as input and
receive as output probabilistic estimates of [ psychological states').
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mutations, perhaps indicating an increased susceptibility to certain
diseases, mental abnormalities, or behaviors.
Some predict that it may be up to a decade before a fully
automated quantitative brain map is clinically available.13 8 However,
it could be much sooner. Nora Volkow, director of the U.S. National
Institute on Drug Abuse, is already impressed by the "mindboggling"
consistency of the data published in the analysis of the 1000
Functional Connectomes Project. 13 9 She recently stated, "I could use
that data set to assess whether the connectivity patterns that I'm
seeing in my patient actually differ in any significant way from this
140
data set, which I can use as reference."'
An excellent example of how a functional neuroimage can show
an asymptomatic individual to be predisposed to a disease comes in
the field of Alzheimer's disease research. Brain imaging has enabled
researchers to better understand vulnerability to Alzheimer's disease
and the mechanisms leading to disease onset.' 4 ' As recently as a few
decades ago, a compartmentalized model of Alzheimer's disease was
widely accepted in the field. 142 Researchers believed that "people
either had [Alzheimer's disease] pathological changes, in which case
they had dementia, or they did not have such changes and were
cognitively normal."'143 With advancements in neuroscience technology,
however, an amended view of the disease has developed. It is now
believed that "both [Alzheimer's disease] pathological processes and
clinical decline occur gradually over time, with dementia representing
the end stage of many years of accumulation of these pathological
changes."'1 In addition, these pathological changes begin to develop
45
decades before the earliest clinical symptoms manifest.1
Neuroimaging studies have revealed neuroimaging correlates of

138. See Yarkoni, supra note 134, at 494 box 3 (predicting that in ten years, there will be
"fully automated quantitative mapping between cognitive and neural states").
139. Dolgin, supra note 129, at 351.
140. Id.
141. Martha J. Farah, Neuroethics: An Overview, in MARTHA J. FARAH, NEUROETHICS, AN
INTRODUCTION WITH READINGS 1, 4 (2010).

142. Clifford R. Jack et al., Hypothetical Model of Dynamic Biomarkers of the Alzheimer's
Pathological Cascade, 9 LANCET NEUROLOGY 119, 119 (2010).
143. Id.
144. B.C. Dickerson et al., Alzheimer-Signature MRI Biomarker Predicts AD Dementia in
Cognitively Normal Adults, 76 NEUROLOGY 1395, 1395 (2011) (discussing how Alzheimer's
disease neuropathology develops "in cognitively normal (CN) adults and caus[es] dysfunction and
cell death in neuronal systems subserving cognition, eventually leading to the clinical
syndrome'); Jack et al., supra note 142, at 119.
145. Dickerson et al., supra note 144, at 1402; Jack et al., supra note 142, at 119.
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incipient Alzheimer's disease, which, in some cases, may herald the
clinical onset several years in advance. 146
While the exact neuropathological process is yet to be fully
understood, currently available evidence suggests the initiating event
in the disease is the abnormal processing of beta amyloid peptide.147
This abnormal processing leads to the formation and depositing of
amyloid plaques, neuronal degeneration, and, ultimately, cognitive
impairment. 148 Scientists are now able to use various neuroimaging
scans, particularly MRI and PET scans, to look into the brains of
healthy living individuals and see the extent to which beta amyloid
protein coats their neurons, forming amyloid plaques, 149 and the
extent to which their
brains are experiencing
neuronal
degeneration. 50 Although most people develop some plaques and
experience some cell degeneration as they age, those with Alzheimer's
tend to do so far more and tend to do so in a predictable pattern,
beginning in areas important for memory before spreading to other
regions. 15 1 Scientists cannot yet accurately calculate the likelihood
that someone with a given amount of amyloid plaque or atrophy in
certain regions of the brain at age forty will have Alzheimer's disease
at age sixty-five, but in a few years this should be possible.1 52
One recent study found that cortical thinning, a brain
abnormality associated with neuronal degeneration, is detectable in
asymptomatic individuals nearly a decade before they are diagnosed
with Alzheimer's disease dementia and is useful not only for assessing
risk of Alzheimer's disease but also for predicting the amount of time
before the onset of dementia. 153 The study looked at the cortical
thickness of certain regions of the brain known to be associated with
Alzheimer's disease and found that the thickness corresponded to the
likelihood that an individual would develop Alzheimer's disease over
the next decade. 54 Researchers scanned the brains of individuals and
measured their cortical thickness and then followed the subjects for
146. Dickerson et al., supra note 144, at 1395-96; Jack et al., supra note 142, at 119.
147. Jack et al., supra note 142, at 119.
148. Id.
149. Greely, supra note 106, at 689.
150. Dickerson et al., supra note 144, at 1395-96.
151. See Dickerson et al., supra note 144, at 1395 (discussing cell atrophy); What is
Alzheimer's?, ALZHEIMERS ASS'N, http://www.alz.org/alzheimersdiseasewhat-is-alzheimers.as
p#brain (last visited Jan. 10, 2011) (discussing plaques and tangles).
152. Greely, supra note 106, at 690.
153. Dickerson et al., supra note 144, at 1395.
154. Id. at 1396, 1398.
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ten years to determine whether they developed the disease. 15 5 Of the
individuals found to have a baseline low thickness, fifty-five percent
developed the disease.156 In contrast, only twenty percent of those with
average baseline thickness developed the disease, while none of the
individuals with high baseline thickness developed the disease. 157
Further, the researchers found that of those individuals who
developed Alzheimer's disease, the baseline thickness was a strong
predictor of the time the individuals had before dementia manifested:
those with the lowest baseline thickness developed the disease faster
than those with relatively higher baseline thickness. 158 Similar efforts
are also underway to use fMRI to find neural correlates of other
neurological disorders, such as Parkinson's disease 159 and multiple
sclerosis. 60 Scientists are also close to being able to predict mental
disorders, such as schizophrenia' 6' and depression, 162 based on
neuroimaging.
Furthermore, just like genetics, neuroimaging also affords the
possibility of predicting future behavior. Several neuroscience studies
show promise in predicting an individual's predisposition to future
dangerousness by finding that the structure and functioning of the
brain of a psychopath are different from those of a nonpsychopath

155. Id. at 1396.
156. Id. at 1398.
157. Id.
158. Id. at 1398, 1400 fig.3.
159. Cornelius Weiller et al., Role of Functional Imaging in Neurological Disorders, 23 J.
MAGNETIC RESONANCE IMAGING 840, 850 (2006).
160. Id.
161. In a study of individuals at risk for developing schizophrenia, researchers found
evidence suggesting that the onset of brain volume decrement may closely pre-date the overt
manifestations of schizophrenia, making brain volume abnormalities potential predictors for
early identification. See Beng-Choon Ho, MRI Brain Volume Abnormalities in Young,
Nonpsychotic Relatives of Schizophrenia Probands Are Associated with Subsequent Prodromal
Symptoms, 96 SCHIZOPHRENIA RES. 1, 13 (2007) (finding that with prodromal symptoms assessed
in these individuals one year after the MRI scans, initial grey matter deficits as well as larger
white matter volumes correlated significantly with greater severity of subsequent prodromal
symptoms).
162. One prospective study conducted a CT scan of 525 elderly subjects without depression
and then compared the images to the development of major and minor depression in the subjects
at a five-year follow-up. Pernille J. Olesen et al., Temporal Lobe Atrophy and White Matter
Lesions Are Related to Major Depression Over 5 Years in the Elderly, 35
NEUROPSYcHOPHARMACOLoGY 2638, 2638-45 (2010). The study concluded that the presence of
temporal lobe atrophy independently predicted major depression, after controlling for various
confounders. Id.
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starting from a young age. 163 Numerous studies suggest that the
presence of an abnormal brain electrical response following
demanding attentional stimuli, emotional word stimuli, and concrete
or abstract work stimuli is "nearly diagnostic" of psychopathy. 164 In
one study, forty of forty-one criminal psychopaths were characterized
by the presence of the particular brain electrical response, while none
of the thirty-nine nonpsychopathic individuals exhibited the
response. 165 In fact, PET images have already been used in criminal
cases to argue that a defendant was biologically predisposed to
committing a crime and should, therefore, be spared a conviction or
death sentence. 66 Kent Kiehl, an expert in the field, predicts that
"within a few years the field of psychopathy will parallel other, more
mature, research fields that have made excellent progress using
neuroimaging techniques as diagnostic tools." 67
Similarly, some scientists maintain that socially relevant
characteristics, such as unconscious racial attitudes, have detectable
neural correlates. In a now well-known and controversial study,
Elizabeth Phelps and colleagues at New York University "used fMRI
to explore the neural substrates involved in the unconscious
evaluation of Black and White social groups." 168 Researchers used
previously developed behavioral measures to estimate the degree of
unconscious racial bias of the subjects and then used fMRI to acquire
brain images from the subjects while presenting them with pictures of
unfamiliar Black and White faces. 69 The study found that variability
in the activation of the amygdala of subjects-a region associated with
emotional learning and that registers fear--correlated with the
163. SAGE CIR. FOR THE STUDY OF THE MIND, UNIV. OF CAL. SANTA BARBARA, A JUDGE'S

GUIDE TO NEUROSCIENCE: A CONCISE INTRODUCTION 49 (2010) (discussing studies that support
the hypothesis that the emotional regions of the brain, the limbic or paralimbic system, are
disordered in psychopathy starting from a very early age).
164. Id. at 50.
165. Kent Kiehl et al., Brain Potentials Implicate Temporal Lobe Abnormalities in Criminal
Psychopaths, 115 J. ABNORMALPSYCHOL. 443-53 (2006).
166. Judy IUes & Eric Racine, Imaging or Imagining? A Neuroethics Challenge Informed by

Genetics, 5 AM. J. BIOETHICS 5, 18 (2005). Evidence of brain damage to explain a defendant's
history of criminally violent behavior could also be used against a defendant, as the jury may
conclude that the defendant is beyond rehabilitation and likely to act criminally again in the
future. See Cullen v. Pinholster, 131 S. Ct. 1388, 1410 (2011) (holding that new evidence of brain
damage is "by no means clearly mitigating, as the jury might have concluded that [the
defendant] was simply beyond rehabilitation").
167. SAGE CTR. FOR THE STUDY OFTHE MIND, supra note 163, at 51.
168. Elizabeth A. Phelps et al., Performances on Indirect Measures of Race Evaluation
Predicts Amygdala Activation, 12 J. COGNITIVE NEUROSCIENCE 729, 729 (2000).
169. Id. at 730-33.
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previously measured degree of unconscious bias. 170 This led to the
conclusion that "representations of social groups that differ in race
evoke differential amygdala activity and such activation is related to
17 1
unconscious social evaluation."'
In reacting to Phelps's research, some speculated that
functional neuroimaging could reveal individuals' racial preferences
and prejudices. 172 In response, Phelps issued a statement expressly
warning against hastily jumping to such conclusions, stating that such
research methods "should not and cannot be assumed.. . to reveal an
individual's hidden racism."' 73 Further, she warned that it would be
"improper to use [the methods] in any selection or diagnostic
context."'174 Nevertheless, many still insist that, at the very least, the
results show the ability to detect the seeds of racial prejudice which
could or could not become actual racism. 75 Relatedly, neuroscientists
176
are investigating neurological predisposition to pedophilia,
177 sexual preference, 178 political preference, 179
compulsive gambling,
8
extroversion and introversion, 8 0 and cooperativeness.' '

170. Id. at 732-33.
171. Id. at 733.
172. Stacey A Tovino, Functional Neuroimaging Information: A Case for Neuro
Exceptionalism? 34 FLA. ST. U. L. REV. 415, 426 (2006) (discussing articles, as well as news and
radio headlines, following Phelps's research).
173. Press Release, N.Y. Univ., NYU/Yale Research Team Explores Neural Basis of Racial
Evaluation (Sept. 18, 2000), available at http:/www.sciencedaily.com/releases/2000/09/00091320
3757.htm.
174. Id.
175. Austin Cline, Brain Privacy:Are Your Thoughts Safe? MRIs Revealing More than Even
You Know About Yourself, ABOUT.COM, http://atheism.about.com/library/FAQs/phil/blphil-ethbio
_brainpriv.htm (last visited Jan. 16, 2011).
176. See Martin Walter et al., Pedophilia Is Linked to Reduced Activation in Hypothalamus

and Lateral Prefrontal Cortex During Visual Erotic Stimulation, 62 BIOLOGICAL PSYCHIATRY
698, 698-701 (2007) (finding abnormal activation in subcortical and cortical regions in pedophilia

during visual-erotic stimulation with adults).
177. See Paolo Cavedini et al., FrontalLobe Dysfunction in Pathological Gambling Patients,
51 BIOLOGICAL PSYCHIATRY 334, 334-41 (2002) (finding a link between pathological gambling
and other disorders that involve a diminished ability to evaluate future consequences, which
may be explained by an abnormal functioning of the orbitofrontal cortex).
178. See Felicitas Kranz & Alumit Ishai, FacePerception Is Modulated by Sexual Preference,
16 CURRENT BIOLOGY 63, 63 (2006); Dick F. Swaab, Sexual Orientationand its Basis in Brain
Structure and Function, 105 PROC. NATAL ACAD. Sci., 10,273, 10,273 (2008), available at
http://www.pnas.org/content/105/30/10273.full.pdf (finding that viewing a female face produced a
strong reaction in the reward circuitry of the thalamus and medial prefrontal cortex of
heterosexual males and homosexual women, whereas in homosexual males and heterosexual
women, these structures reacted more strongly to the face of a man).
179. See John Tierney, Using MR.I. "sto See Politics on the Brain,N.Y. TIMES, Apr. 20, 2004,
at Al (finding that images of the September 11, 2001, terrorist attacks caused the amygdala, an
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B. Imperfect Predictionand Employer Misuse
Advancements in predictive neuroimaging may aid in the
identification of neural structure and function underlying disease and
behavior and may even raise the possibility to cure some diseases.
However, like genetic testing, this scientific accomplishment is not
without potential problems. Neuro information suffers from the same
imperfections that plagued genetic testing-brain images indicating a
propensity for disease or behavior do not necessarily mean that the
disease or behavior will materialize.
No less than the genome, the brain is "an extraordinarily
complex combinatorial system. '18 2 Despite the recent advancements in
the field, there still remains a sizeable gap between the ability to
identify existing brain structures and functioning and the
understanding of their corresponding implications for an individual's
health and behaviors.18 3 In addition, the brain image itself represents
unparalleled complexity-from the specialized medical equipment
needed to acquire a scan, to the array of parameters used to elicit
activations and the statistical thresholds set to draw out meaningful
patterns, to the expertise required for the interpretation of the maps
themselves.'84 These limitations in scientific understanding, the
shortcomings of the underlying technology, and the subjective nature
of interpretation leave room for error, variation, and bias in
neuroimaging test results.18 5 Therefore, and of great relevance to
area of the brain associated with fear and anger, to light up more vividly in Democrats than in
Republicans).
180. See Turhan Canli et al., An fMRI Study of PersonalityInfluences on Brain Reactivity to
Emotional Stimuli, 115 BEHAV. NEUROSCIENCE 33, 33 (2001) (finding that in response to
emotionally evocative stimuli, certain regions of the brain were activated in different degrees
among patients identified as possessing the personality trait extroversion versus those with
neuroticism).
181. See James K. Rilling et al., A Neural Basis for Social Cooperation, 35 NEURON 395, 395
(2002) (finding that when researchers scanned the brains of subjects as they played the
Prisoner's Dilemma, mutual cooperation was associated with consistent activation in regions of
the brain linked to reward processing, proposing that the pattern of neural activation positively
reinforced reciprocal altruism, thereby motivating subjects to resist the temptation to act in their
immediate self-interest).
182. Ronald M. Green, From Genome to Brainome: Charting the Lessons Learned, in
NEUROETIICS: DEFINING THE ISSUES IN THEORY, PRACTICE, AND POLICY 105, 114 (Judy Illes ed.,
2004).
183. Id. at 113.
184. Turhan Canli & Zenab Amin, Neuroimaging of Emotion and Personality: Scientific
Evidence and Ethical Consideration, 50 BRAIN & COGNITION, 414, 424-26 (2002); Committee on
Science and Law, supra note 113, at 435; Illes & Racine, supra note 166, at 8 tbl.1.
185. Committee on Science and Law, supra note 113, at 435.
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disease and behavior prediction, neural pathways that are structured
or function one way in one individual can produce entirely different
outcomes in another. For example, one study noted that while damage
to the ventromedial prefrontal region of the brain is associated with
acquired sociopathy, it is also true that there are individuals who have
all the expected structural characteristics for the disease but who

never exhibit

it.186

Thus, "even dramatic cerebral anomalies or

idiosyncrasies may not correspond to predictable behaviors, thoughts,
87
or emotions" across individuals.
Barbara Koenig, associate professor of medicine and former
executive director of the Stanford Center for Biomedical Ethics,
worries in particular about the misuse of such probabilistic
information on future disease and behavior. Koenig has said, "[T]he
brain offers a seductive promise of prediction. Whether or not those
predictions prove to be scientifically accurate may be less important
than our belief in their power."' 8 8 As discussed in the congressional
debate leading to the enactment of GINA, although predictive testing
may be only probabilistic, it may still prove economically efficient from
the perspective of an employer to rely on the information in making
employment decisions.1 8 9 In pre-employment testing, an employer may
not require certainty that an individual will manifest a disease or
evidence a harmful trait.1 90 Merely probabilistic information is
valuable in that it conveys the knowledge that the possession of a
particular DNA sequence, or brain function or structure, places the
applicant at a higher risk of doing so. 191 When processing large
numbers of applicants, an employer can significantly reduce costs by
denying employment to those whose test results show them to be at a
92
higher risk for a disease or other detrimental trait.
For example, an employer may be financially incentivized to
use neuroimaging correlates of Alzheimer's disease in making its
hiring decisions. Aside from the emotional toll that Alzheimer's
disease can have on both the patient and caregivers, the disease
creates staggering financial burdens. The average lifetime cost of care

186. Green, supra note 182, at 114 (discussing the study, Jorge Moll et al., Morals and the
Human Brain:A Working Model, 14 NEUROREIoRT 299, 300 (2003).
187. Id. at 109.
188. Hamilton, supra note 10.
189. See discussion supraPart I.B.
190. Green, supra note 182, at 113.
191. Id.
192. Id.
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for an individual with the disease is $170,000.193 Alzheimer's disease
costs businesses in the United States $61 billion annually, according
to a report commissioned by the Alzheimer's Association. 94 Of that
figure, $24.6 billion go toward Alzheimer health care, and $36.5 billion
95
result from lost productivity, absenteeism, and worker replacement.
Furthermore, the costs to businesses are only expected to rise: experts
project the prevalence of Alzheimer's disease to quadruple by 2050.196
This means that one in every forty-five Americans will be afflicted
with the disease. 197 What if an employer could predict with some
degree of probability, out of forty-five job applicants, who that one was
going to be? As discussed above, this may soon, if not already, be a
real possibility. Furthermore, with it now illegal to use genetic testing
in this context, neuroimaging may be an attractive alternative for
employers.
C. InadequateExisting Federal Statutory Protections
Just as Congress found there was insufficient existing
protection against genetic-information acquisition and misuse preGINA, 198 existing federal statutes are inadequate to protect against
the acquisition and misuse of neuro information by employers.1 99 The
insufficient protections afforded to neuro information by Title VII of
the Civil Rights Act of 1964 and by Executive Order 13,145 are, again,
readily apparent. Title VII is limited to barring discrimination in
employment on the basis of race, color, religion, sex, and national
origin. 20 0 Therefore, employees and job applicants can prevail on Title
VII claims only if they establish that the employer singled out a
specific protected class for neuroimaging. 20 1 Executive Order 13,145
prohibits federal departments and agencies from taking adverse
employment actions based on employees' "protected genetic
193. Richard L. Ernst & Joel W. Hay, The U.S. Economic and Social Costs of Alzheimer's
Disease Revisited 84 AM. J. PUB. HEALTH 1261, 1262 (1994).
194. ROSS KOPPEL, AIZHEIMER'S ASS'N, AiZHEIMER'S DISEASE: THE COSTS TO U.S.
BUSINESSES IN 2002, at 2 (2002).
195. Id.
196. Claudia H. Kawas & Ron Brookmeyer, Aging and the Public Health Effects of Dementia,
344 NEW ENGLAND J. MED. 1160, 1160-61 (2001).
197. Id.
198. See discussion supra Part I.C.
199. See Tovino, supra note 172, at 465-69 (discussing the lack of sufficient protection
afforded to neuroimaging information by currently existing federal statutes).
200. 42 U.S.C. § 2000e-2(a) (2006).
201. See discussion supra Part I.C.
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information" 202 and therefore does not even apply to neuro
information. Also consistent with the congressional findings in the
context of genetic information, the ADA does not protect workers from
requirements or requests to provide neuro information to their
employers or from an employer purchasing an employee's neuro
information from a data bank, once a job offer of employment has been
made but before the individual begins work. 203 Worth further inquiry
is whether neuro information is protected by the ADA Amendments
Act's ("ADAAA")204 expanded definition of "disability," enacted shortly
after the passage of GINA, and whether acquisition of and
discrimination based on neuro information is protected by the Federal
Employee Polygraph Protection Act of 1988 ("EPPA")205-a statute
particular to neuroimaging that was not discussed in the debates
leading to the enactment of GINA.
The ADAAA was enacted on September 25, 2008, with the
purpose of "reinstating a broad scope of protection." 20 6 The
Amendments retained the broad definition of "disability" to include an
individual with "a physical or mental impairment that substantially
limits one or more major life activities of such individuals" and an
individual "being regarded as having such an impairment" and made
no explicit mention of neuro information. 20 7 The ADAAA, however,
expanded the definition of "disability" in two ways: (1) by clarifying
that the term "major life activities" includes "major bodily functions";
and (2) by lessening what is required to come within the "regarded as"
prong.
First, the ADAAA revised the definition of "major life
activities" to include "the operation of bodily function, including but
not limited to, functions of the immune system, normal cell growth,
digestive, bowel, bladder, neurological, brain, respiratory, circulatory,
endocrine, and reproductive functions." 208 Previously, the EEOC had
202. 65 Fed. Reg. 6877, 6878 (Feb. 10, 2000).
203. See discussion supra Part IC; see also Tovino, supra note 172, at 466-67 (discussing
how at the "preplacement stage" an employer could require an employee to consent to a "broad-

based fMRI screening"). Further, once the applicant is hired, the employer may request medical
information, including neuro information, that is considered job related and consistent with
business necessity. Id. at 467.
204. ADA Amendments Act of 2008, Pub. L. No. 110-325, 122 Stat. 3553 (amending sections
of 42 U.S.C.).
205. Federal Employee Polygraph Protection Act ("EPPA") of 1988, Pub. L. No. 100-347, 102
Stat. 646 (codified as amended at 29 U.S.C. §§ 2001-2009 (2006)).
206. ADA Amendments Act § 2(b)(1), 122 Stat. at 3554 (codified at 42 U.S.C. § 12101).
207. § 4(a), 122 Stat. at 3555 (codified at 42 U.S.C. § 12102(1)).
208. § 4(a), 122 Stat. at 3555 (codified at 42 U.S.C. § 12102(2)(B)).
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taken the position that "major life activities" included only "basic
activities" such as walking, speaking, communicating, and working. 20 9
Thus, under the amended definition, an individual will now be
considered to have a "disability" if he or she currently has an
impairment that substantially limits major bodily functions,
regardless of whether the impairment would substantially limit what
one generally considers day-to-day activities. To determine whether
this new addition to the definition of "major life activities" would cover
neural correlates that predict future onset of disease, a further inquiry
must be made into the ADAAA's meaning of "substantially limits."
The ADAAA expressly rejected the strict standard previously
enunciated by the Supreme Court in Toyota Motor Manufacturing,
Kentucky, Inc. v. Williams,210 that to be substantially limited in
performing a major life activity under the ADA, "an individual must
have an impairment that prevents or severely restricts the individual
from doing activities that are of central importance to most people's
daily lives. ' '2 11 While in rejecting this standard the statute might
provide some guidance in determining whether an impairment
substantially limits what the EEOC traditionally considered to be
"major life activities," it provides little help in determining whether an
impairment limits major bodily functions. In fact, neither the text of
the ADAAA nor the recently enacted EEOC regulations clarify exactly
what it means to substantially limit major bodily function. The new
EEOC regulations do, however, provide a list of illustrative examples
that seem to suggest that neural correlates for disease in
asymptomatic individuals would not be considered an impairment
substantially limiting brain or neurological function. In describing
impairments that substantially limit brain and neurological function,
the EEOC exclusively lists conditions that are currently manifested
and diagnosable. 212 For instance, the EEOC states that cerebral palsy,
autism, bipolar disorder, obsessive -compulsive disorder, and
schizophrenia substantially limit brain function. 213 Similarly, the
EEOC regulations state that muscular dystrophy and epilepsy
substantially limit neurological function. 2 14 Thus, while the ADAAA

209. U.S. EQUAL EMPT OPPORTUNITY COMM'N, COMPLIANCE MANUAL § 902 (1995).
210. 534 U.S. 184 (2002).
211. ADA Amendments Act § 2(b)(4), 122 Stat. at 3554 (codified at 42 U.S.C. § 12,101(b)(4)).
212. See 29 C.F.R. § 1630.2(j) (2011) (listing conditions that would be considered to
substantially limit major bodily function).
213. 29 C.F.R. § 1630.2(j).
214. Id.
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clearly protects employees once they have developed a neurological or
psychological condition, it fails to address whether an employee's
neuro information, which indicates the likelihood of developing a
future condition, can constitute an impairment that substantially
limits one or more major life activities.
Second, the ADAAA clarified that an individual is "regarded as
having such an impairment" if the individual has been subjected to
adverse employment action "because of an actual or perceived physical
or mental impairment whether or not the impairment limits or is
perceived to limit a major life activity. ' 215 In doing so, the ADAAA
expressly rejected the Supreme Court's more burdensome reasoning in
Sutton v. United Air Lines, Inc.,216 that to come within the "regarded
as" prong, an employer "must believe either that one has a
substantially limiting impairment that one does not have or that one
has a substantially limiting impairment when, in fact, the impairment
is not so limiting." 217 However, it is still unclear whether an employee
fired for a not-yet-manifested condition could claim that the employer
perceived him or her as having an impairment. The new standard still
appears to require that the employer perceived the individual as
currently having an impairment, regardless of whether or not the
individual actually has the impairment, and regardless of whether or
not the impairment limits or is perceived by the employer as limiting a
major life activity. Therefore, for the time being, it seems that an
employer that takes adverse employment action against an individual
due to neuro information indicating propensity to manifest an
impairment in the future would not be considered to be perceiving the
individual as currently having an impairment. Furthermore, the likely
protection provided for by the statute in the context of predictive
neuroimaging is even less promising than it was in the context of
genetic testing. Unlike for genetic information, the EEOC has not
supported the position that the ADA "regarded as" prong protects
individuals with neural correlates for illness, disease, or disorders
from discrimination in employment. Overall, even though the ADAAA
was enacted to provide a broader scope of protection, it still would not
sufficiently prohibit employers from using neuro information to

215. ADA Amendments Act § 4(a), 122 Stat. at 3555 (codified at 42 U.S.C. § 12,102).
216. 527 U.S. 471 (1991).
217. See ADA Amendments Act § 2(b)(3), 122 Stat. at 3554 (codified at 42 U.S.C. 12101)
(rejecting the Court's reasoning in Sutton, in favor of a more broad view with regards to coverage
under the third prong of the definition of disability).
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predict the future health of job applicants and to discriminate on that
basis.
An additional source of protection that must be considered in
conjunction with neuroimaging is EPPA. 218 EPPA prohibits private
employers from directly or indirectly requiring or requesting that
employees or job applicants submit to any lie detector test. 2 19 In
addition, covered employers cannot accept or use the results of such a
test nor can they take any adverse employment action against an
employee or applicant for refusal to take such a test or on the basis of
such test results. 220 The statute also restricts who can disclose
information obtained from a lie detector test. 221
EPPA defines the term "lie detector" broadly to include "a
polygraph, deceptograph, voice stress analyzer, psychological stress
evaluator, or any other similar device (whether mechanical or
electrical) that is used, or the results of which are used, for the
purpose of rendering a diagnostic opinion regarding the honesty or
dishonesty of an individual." 222 Numerous studies have demonstrated
that neuroimaging is capable of detecting deception, and, in fact,
several companies are currently marketing their neuroimaging lie
detection services directly to employers for such purposes. 223
Presumably, neuroimaging would come within the "any other similar
device" prong of the statute's definition of "lie detector" if the exam or
results were used for detecting honesty or dishonesty. Therefore, for
the moment, it seems that EPPA could be interpreted to prohibit
covered employers from requiring neuroimaging examinations to form
the basis of an opinion regarding an individual's dishonesty and from

218. Federal Employee Polygraph Protection Act ('EPPA") of 1988, Pub. L. No. 100-347, 102

Stat. 646 (codified as amended at 29 U.S.C. §§ 2001-2009 (2006)).
219. 29 U.S.C. § 2002.
220. Id.
221. 29 U.S.C. § 2008. Such information may be disclosed by an examiner only to: the
examinee or a person designated by him or her; the employer that requested the test; or any
court, governmental agency, arbiter, or mediator in accordance with a court order requiring the
production of such information. Id. The employer who requested the test may disclose its results
only to the employee or to a government agency, but only insofar as the information is an
admission of criminal conduct. Id.
222. 29 U.S.C. § 2001(3) (emphasis added).
223. See SAGE CTI. FOR THE STUDY OF THE MIND, supra note 163, at 13-23 (discussing
numerous peer-reviewed studies on the use of neuroimaging to detect deception); CustomersCorporations, No LIE MRI, httpl/noliemri.comcustomers/GroupOrCorporate.htm (last visited
Jan. 26, 2012) (discussing how No Lie MRI could be used by corporations as a substitute for drug
screenings, resume validations, and security background checks, leading to a streamlined hiring
process and a more honest employee base).
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using such results to take adverse employment action. 224 However,
neuroimaging would not come within the definition of "lie detector" if
the exam or results were used for nondeception reasons, such as to
form a conclusion about future propensity to disease. 22 5 Thus, EPPA
would still not provide any limitation on an employer requesting an
employee or applicant to submit to neuroimaging exams for such
nondeception reasons or any limitation on the employer using the
results of such nondeception neuroimaging exams in making
employment decisions.

224. Tovino, supra note 172, at 468; see also Committee on Science and Law, supranote 113,
at 414-15 (submitting that various forms of brain imaging would likely constitute a lie detector
under EPPA if used to detect honesty or dishonesty). But see Customers-Corporations,NO LIE
MRI, httpJ/noliemri.com/customers/GroupOrCorporate.htm (last visited Jan. 26, 2012) (stating
that No Lie MRI is "unaware of any law that would prohibit its use for employment screening").
The company implies that EPPA only "prohibits truth verification/lie detection testing for
employees that is based on measuring the autonomic nervous system (e.g. polygraph testing),"
and since MRI "measures the central nervous system directly," it is "not subject to restriction by
these laws." Id. Furthermore, the court in Veazey v. Communications & Cable of Chicago, Inc.
stated that in order to understand and interpret EPPA, it is helpful to consider the history of the
lie detector and its impact on employees. 194 F.3d 850, 855 (7th Cir. 1999). Congress enacted
EPPA in 1988 in response to concerns that employers were often misusing lie detectors or their
derivatives and were too frequently relying on inaccurate, inconclusive, or unfounded lie detector
results to make employment decisions. Id. at 858 (citing S. REP. NO. 100-284, at 46 (1988),
reprinted in 1988 U.S.C.C.A.N. 726, 734). In passing the statute, Congress considered many
studies about the reliability of polygraph techniques and the efficacy of countermeasures taken
by the examinee deliberately to obscure accurate readings with several studies showing accuracy
rates of sixty percent and below. Id. at 855-58 (discussing multiple studies); see, e.g., J. KUBIS,
U.S. ARMY LAND WARFARE LAB., TECH. REPORT NO. LWL-C103B70, COMPARISON OF VOICE
ANALYSIS AND POLYGRAPH AS LIE DETECTING PROCEDURE (1973) (finding accuracy rates of below
sixty percent); Gordon H. Barland & David C. Raskin, An Evaluation of Field Techniques in
Detection of Deception, 12 PSYCHOPHYSIOLOGY 321, 321 (1975) (noting an error rate of fifty-five
percent). Therefore, it is unclear under this reasoning whether neuroimaging technology that
detects lies with greater accuracy would be covered by the statute.
225. A more complex question is whether EPPA would protect against an employee's neuro
information regarding his ability or propensity to deceive. In fact, a recent study indicates that
fMRI may be used to show an individual's ability to deceive intentionally by having the test
subject respond truthfully or falsely to a series of yes/no questions regarding autobiographical
information. Jennifer M. Nunez et al.,
Intentional False Responding Share Neural Substrates
with Response Conflict and Cognitive Control, 25 NEUROIMAGE 267-77 (2005). It is unclear
whether this kind of neuro information would be protected under EPPA, because the test
indicates an individual's propensity or ability to deceive as a personality or behavioral
characteristic-not whether they are or are not telling the truth in response to a specific question
or set of questions.
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III. ADDITIONAL CONSIDERATIONS RELEVANT TO NEUROSCIENCEBASED DISCRIMINATION: NEUROENHANCEMENT
The predictive ability of brain scanning is not the only
neurotechnology that raises issues of employment discrimination.
Drug companies are pushing ahead with neuropharmaceuticals, which
are able to manipulate a person's strength, memory, ability to
concentrate, and capacity to learn above "normal." Once these drugs
are available, the pressures of the marketplace-not to mention
potential military uses-may compel society to embrace them to
remain competitive. 226 In fact, considering the financial appeal that
these drugs may have to employers by way of increasing employee
alertness and improving cognitive performance and productivity,
employers may wish to discriminate against applicants and employees
based on the use or nonuse of neuroenhancements.
Attempts by human beings to use chemical substances to alter
normal affective and cognitive traits are as old as drinking coffee or
alcohol. 227 Until recently, however, pharmaceutical options had either
limited effectiveness or significant risks of addiction and side effects
that limited their attractiveness and ability to be extensively used as
an employment discrimination technique. 228 This situation is
changing. Several neuropharmaceuticals for cognitive enhancement
have already been approved by the Food and Drug Administration
("FDA") and are being utilized by the military, long-distance business
travelers, and ambitious entrepreneurs. The Defense Advanced
Research Projects Agency ("DARPA'), the central research and
development organization for the Department of Defense, has invested
millions of dollars through its Preventing Sleep Deprivation program
in developing neuropharmaceuticals that could act as a human
enhancement drug in minimizing sleep while also retaining cognitive
capacity. 229 In its own words, DARPA "is investigating ways to prevent
fatigue and enable soldiers to stay awake, alert, and effective for up to
seven days straight without suffering any deleterious mental or

226. Anjan Chatterjee, The Promise and Predicament of Cosmetic Neurology, 32 J. MED.
ETHICS 110, 111 (2006).
227. Martha J. Farah & Paul Root Wolpe, Monitoring and Manipulating Brain Function:
New Neuroscience Technologies and Their Ethical Implications, 34 HASTINGS CTR. REP., MayJune 2004, at 35, 41.
228. Id.
229. MORENO, supra note 114, at 116-18.
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physical effects and without using any of the current generation of
230
stimulants."
One drug that has shown promise in accomplishing this goal is
modafinil. Modafinil, marketed as Provigil®, was developed by a
French firm to fight narcolepsy and sold to U.S. drugmaker
Cephalon. 23 1 The French Foreign Legion used the drug in Gulf War I,
and unconfirmed news sources report that coalition troops used the

substance during the drive to Baghdad in early

2003.232

Rather than

stimulating the entire central nervous system like an amphetamine
would, modafinil "nudges the brain toward wakefulness through
specific pathways." 23 3 The compound can therefore keep users awake
for two or three days with negligible side effects and little risk of
23 4
addiction.
Other than soldiers and individuals suffering from neurological
disorders, modafinil has received attention from long-distance
business travelers and is expected by many to be the next craze on
college campuses, replacing stimulants such as Ritalin. 235 In fact, the
drug has already been referred to as the "entrepreneur's drug of
choice" around Silicon Valley, where some executives say they use it
regularly to work twenty-hour days. 23 6 Although a prescription is
needed for the drug, it may be easier to get from a doctor than one
may think. Modafinil is approved in the United States to treat several
neurological disorders, but also to treat "shift work sleep disorder." 237
Shift work sleep disorder is generously described as sleepiness during

230. Jonathan Moreno, DARPA On Your Mind, 6 CEREBRUM 92, 94 (2004).
231. Richard Martin, It's Wake-Up Time, WIRED, Nov. 2003, http://www.wired.com/wired/
archive/11.11/sleep.html.
232. MORENO, supranote 114, at 115; Martin, supra note 231.
233. MORENO, supra note 114, at 115.
234. Scott Grady et al., Effect of Modafinil on Impairments in NeurobehavioralPerformance
and Learning Associated with Extended Wakefulness and Circadian Misalignment, 35
NEUROPSYCHOPHARMACOLOGY 1910, 1910 (2010).
235. MORENO, supra note 114, at 115.
236. Michael Arrington, How Many Silicon Valley Startup Executives Are Hopped up on
Provigil? TECH CRUNCH (July 15, 2008), http://techcrunch.com/2008/07/15/how-many-of-ourstartup-executives-are-hopped-up-on-provigi]/. Also, famous American basketball player Diana
Taurasi was temporarily suspended by the Turkish Basketball Federation after she tested
positive for the drug during a routine screening. Taurasi Cleared of Drug Accusation, N.Y.
TIMES, Feb. 16, 2011. The lab that conducted the positive test later retracted its report after it
evaluated Taurasi's statements in her defense, repeatedly denying using performance-enhancing
drugs. Id.
237. PROVIG1L http://www.provigil.com/ (last visited Feb. 1, 2012).
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scheduled waking hours for those who work at night or on rotating
238
shifts.
Several studies on the effectiveness of modafinil have even
focused on its utility to healthy employees by replicating the
circumstances of shift workers and measuring cognitive performance.
Cephalon and the Air Force Office of Scientific Research sponsored a
study in which sixteen healthy subjects were deprived of sleep for
twenty-eight hours and then allowed to sleep from 11 a.m. to 7 p.m.
for four days and to stay awake at night. 239 The study found that the
subjects on modafinil did far better on cognitive tests than those given
a placebo. 240 Similar studies have also shown modafinil to be more
effective than caffeine or amphetamines in mitigating adverse effects
on performance or safety associated with prolonged wakefulness, and
without any of the adverse side effects. 241 For example, one recent
study showed that treatment with modafinil significantly attenuated
the performance decrements for cognitive throughput, visual
attention, and reaction times and led to fewer bouts of inadvertent
sleep during scheduled waking.242 The study concluded that these
features "suggest that modafinil might be a particularly relevant
countermeasure against the deleterious effects of prolonged work
hours, shift work, and transmeridian travel."243
DARPA has also been investigating the potential of another
class of drugs: ampakines. 244 Ampakines have shown clinical promise
in treating dementia and symptoms of schizophrenia by improving
cognition when used with antipsychotic medications. 245 Thus, while
modafinil is attractive for its enhancement potential as an antisleep
agent, ampakines are desirable for their potential to improve cognitive
abilities above what are typically thought of as normal. Ampakines
work by binding to AMPA-type glutamate receptors in the brain. 246
238. Id.
239. MORENO, supra note 114, at 116.
240. Id.
241. Grady et al., supranote 234, at 1916-18.
242. Id. at 1915-18.
243. Id. at 1915-16; see also James K. Walsh et al., Modafinil Improves Alertness, Vigilance,
and Executive Function During Simulated Night Shifts, 27 SLEEP 434, 434 (2004) ("The
physiologic sleepiness and neurobehavioral deficits that occurred during the hours of a typical
night shift were clearly attenuated by modafinil.").
244. MORENO, supra note 114, at 118.
245. Id.
246. Julia Boyle et al., Acute Sleep Deprivation: The Effects of the AMPAKINE Compound
CX717 on Human Cognitive Performance, Alertness and Recovery
Sleep,
J.
PSYCHOPHARMACOLOGY, Sept. 2011, at 1.
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This binding boosts the activity of glutamate, a neurotransmitter, and
improves the brain's ability to encode memory and to learn. 247 Because
of their short half-life of only a few hours, ampakines have few side
effects. 248 Thus, these agents can selectively increase cerebral
activation without the deleterious effects of excessive arousal that
may impair performance. 249 A DARPA-funded study at Wake Forest
University School of Medicine has shown that a single dose of CX717,
a type of ampakine, completely reversed deficits in performance
accuracy and reaction time associated with sleep deprivation in
monkeys. 250 In addition, specific changes in the electrical activity of
the brain that occurred after sleep deprivation returned to the nonsleep-deprived state in the CX717 group of monkeys. 251 Even more
exciting, a recent human trial sponsored by Cortex Pharmaceuticals
found that when taken by sixteen healthy men deprived of sleep, the
compound improved their performance on memory and attention tests
252
with minimal side effects.
IV. NEURO INFORMATION NONDISCRIMINATION ACT
Although neuroscientists and ethicists have begun to confer
about the emerging ethical and legal issues stemming from the
advancement in neuroscience research, there has been nothing
comparable to the ELSI initiative in the field. 253 This is important
because ELSI played a pivotal role in the enactment of GINA by
developing a series of recommendations that served as a model for the
future workplace legislation. 25 4 ELSI also paved the way for hundreds
of articles, books, conferences, and other research and educational
activities that made the public aware of the implications of genetics

247. Id. at 1.
248. Allison Motluk, New Drug Offers Jitter-FreeMental Boost, NEW SCIENTIST, May 5, 2005,
http://www.newscientist.com/article/dn7342-new-drug-offers-jitterfree-mental-boost.html.
249. Id.
250. DARPA Extends Research Funding for the Prevention of Sleep Deprivation, Which
Includes AMPAKINE Technology, BUSINESS WIRE, June 8, 2004, available at http://www.
businesswire.com/news/home/20040608005212/en/DARPA-Extends-Research-FundingPrevention-Sleep-Deprivation.
251. Id.
252. Boyle et al., supra note 246, at 10.
253. Green, supra note 182, at 105.
254. Workplace Hearings, supra note 43 (statement of Francis S. Collins, Dir., Nat'l Human
Genome Res. Inst., Natl Insts. of Health).
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and that gave the issue political clout. 2 55 Unlike the HGP, which
devoted three to five percent of its budget to the ethical, legal, and
social implications of such research initiatives, neither the Human
Brain Project nor the Human Connectome Project created such
government funding appropriation. 256 Why is this so? Some believe
that it reflects a lesser degree of government involvement in
neuroscience or fewer public fears about the misuses of neuroscience
research. 257 Whatever the explanation, this departure is not justified.
As this Note argues, developments in neuroscience are just as likely to
have significant effects on ethics, law, and society as those in
genetics, 258 especially in the realm of employment discrimination.
Therefore, federal legislation entitled the Neuro Information
Nondiscrimination Act ("NINA') should be considered to prohibit
employers from (1) requesting, acquiring, or disclosing neuro
information and from discriminating on the basis of neuro
information, and (2) requesting or requiring that applicants or
employees engage in neuroenhancement and from directly or
indirectly discriminating on the basis of the use or nonuse of
neuroenhancement techniques.
A. Title I: Neuro Information, Employer Acquisition, and
Discrimination
Given that brain images, like genetic information, are expected
to predict susceptibility to disease, parallel concerns arise about
ensuring that such information is not relied on to unjustly deny
employment. Neuroimaging is already capable of predicting disease
and behavior on a small scale. In a few years, with discoveries from
the Human Connectome Project and the 1000 Functional
Connectomes Project, such predictions will be possible on a large scale.

255. See Greely, supra note 43, at 604, 623-33 (discussing how the ELSI program led to
extensive educational activities on the implications of genetics and how there was a need for
"political cover' on the issues involved).
256. Committee on Science and Law, supra note 113, at 427.
257. Green, supra note 182, at 105; see also Greely, supra note 43, at 632-36 (discussing how
ELSI was a "product of three factors: a major scientific initiative funded by federal agencies, the
ready availability of money to spend on ethics, and a need for political cover" and how the field of
neuroscience lacks these factors).
258. See also Hamilton, supra note 10 (quoting Judy Illes et al., From Neuroimaging to
Neuroethics, 6 NATURE NEUROSCIENCE 203, 205 (2003) ("Our analysis shows a steady expansion
of studies with evident social and policy implications, including studies of human cooperation
and competition, brain differences in violent people and genetic influences on brain structure and
function.')).
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Nevertheless, despite the advancements in the field, there is, and
surely will remain in the foreseeable future, a gap between the
scientific knowledge needed to identify existing brain structures and
functioning and the understanding of their corresponding implications
for an individual's health and behaviors. Further, the brain image
itself represents unparalleled complexity attributable to the
specialized equipment, statistical thresholds, and expertise required
for interpretation. These limitations in the science and technology will
lead to neuroimaging results in one individual producing entirely
different outcomes in another. However, as illustrated in the context
of genetic information, these technical deficiencies will not deter
employers from finding it economically efficient to acquire such
information and to rely on it in making employment decisions. Since
such predispositional decisionmaking violates society's beliefs in
merit-based advancement, Title I of NINA should mirror Title II of
GINA in preventing the acquisition and misuse of neuro information
by employers.
Many argue, however, that the legal implications of
neuroimaging may be less extensive than those for genetics because of
the difference in accessibility of information between the two fields. 259
With genetics, an individual's complete genome is present in
practically every cell in the body.260 Since people potentially leave
some of their DNA almost everywhere they go, it is relatively easy for
a person-or employer-to obtain a sample of DNA from another
person without his or her knowledge or consent. 261 Furthermore, this
DNA sample is easily convertible into an extraordinary amount of
genetic information-technologies such as polymerase chain reaction
262
make it possible to amplify even the smallest traces of DNA.
Companies have offered genetic tests directly to consumers for years
at low prices. 263 Many have been "hawking tests on the Internet," and
some companies, such as Pathway Genomics, have even attempted to
sell genetic testing devices at Walgreens alongside toothpaste and
deodorant. 264

259. Green, supra note 182, at 107-08.
260. Id. at 107.
261. Id. at 107-08.
262. Id.
263. Id.
264. Rob Stein, Company Plans to Sell Genetic Testing Kit at Drug Stores, WASH. POST, May
11, 2010, at Al.
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While it is true that such ease of unconsented access to neuro
information does not currently exist, technologies are being developed
to overcome such access limitations in the future. 265 More importantly,
however, the main concern of Congress in enacting GINA was not that
employers would test employees without their knowledge, but that
employers could request or require genetic information from
applicants and employees or obtain the genetic information from
research databases. 266 This concern is equally present in the context of
neuro information.
As the price of neurotechnologies continues to decline, the
concern that employers may require that applicants or employees
undergo neuroimaging is likely to materialize. One company currently
markets its fMRI brain-scanning services directly to employers at
thirty dollars per minute, noting that such "scans may not be
prohibitively expensive for all employers, especially those who hire
well-paid professional or executive personnel." 267 Furthermore,
neuroimaging research databases are especially susceptible to
employer misuse. Scientists routinely strip neuroimaging data of
direct identifiers, such as names and birth dates, to render the data
not identifiable prior to data sharing. 268 Although these types of
confidentiality measures may be sufficient in the realm of genetic
information, rendering data not identifiable is further complicated in
the neuroimaging context because of the existence of computer

265. Researchers are currently working on technologies to remotely detect brain activity,
creating the potential in the future for an individual's brain to be scanned without them
consenting or having any knowledge. Nita Farahany, The Government Is Trying to Wrap Its
Mind Around Yours, WASH. POST, Apr. 13, 2008, at B3; see also C.J. Harland et al., Electric
Potential Probes-New Directions in the Remote Sensing of the Human Body, 13 MEASUREMENT
Sci. & TECH. 163, 163 (2002) (reporting on the use of technology to measure the heart at great
distances); C.J. Harland et al., Remote Detection of Human Electroencephalograms Using
UltrahighInput Impedance Electric Potential Sensors, 81 APPLIED PHYSICS LETTERS 3284, 3286
(2002) (showing that it is possible to detect brain electrical activity with a three-millimeter air
gap between the scalp and the sensor); Yu M. Chi, Non-Contact Low Power EEG/ECG Electrode
for High Density Wearable Biopotential Sensor Networks 246-250 (Sixth International Workshop
on Wearable and Implantable Body Sensor Networks, 2009) (reporting that it is possible to
detect brain electrical activity with a three-millimeter air gap between the scalp hair and the
sensor); Yu M. Chi & Gert Cauwenberghs, Wireless Non-Contact EEG/ECG Electrodes for Body
Sensor Networks 297-301 (International Conference on Body Sensor Networks, 2010) (same);
R.J. Prance et al., Biological and Medical Applications of a New Electric Field Sensor 3-4
(Proceedings of the ESA Annual Meeting on Electrostatics, Paper N2, 2008) (reporting on the use
of technology to measure the heart at great distances).
266. See discussion supra Part I.C.
267. Tovino, supra note 172, at 465 (citing e-mails from Joel Huzzeniga, CEO, No Lie MRI, to
author (May 17, 2006, 05:56 CST; May 23, 2006, 12:36 CST) (on file with author Torvino)).
268. Tovino, supra note 172, at 447.
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software capable of generating images of a subject's cranio-facial
features from raw neuroimaging data. 26 9 Indeed, based on various
features of neuroimages, an individual's face can be reconstructed
under certain conditions, thereby providing material for the
270
reidentification of test subjects.
Others contend that while legislation may at some point be
required to protect employees' neuro information, the science and
271
technology are not advanced enough yet to require enacting it now.
However, a lesson should be gleaned from the thirteen-yearlegislative
battle faced by GINA. Senator Olympia Snowe, cosponsor of the
original bill to prohibit genetic discrimination, observed at the time
the bill was first introduced that "the completion of the human
genome seem[ed] far away."272 But, due to the lengthy congressional
debates and timeliness of the bureaucratic process, the science ended
up outpacing congressional action. 2 73 In the time it might take for
congressional action to catch up with neuroscience, the harsh reality is
that people will suffer from inadequate legal protections. 274 Society
"can't afford to take one step forward in science but two steps back in
civil rights." 275 Therefore, it is important to "grapple" with this issue
now by enacting forward-looking legislation before the science and
technology reach their full predictive potential and become part of
everyday life. 276 As Senator James Jeffords championed in the context
of GINA, Congress should "take that rare opportunity to be ahead of
the curve and enact legislation to preempt discriminatory practices
and prevent them from ever happening." 277

269. Id.
270. Arthur W. Toga, Neuroimage Databases: The Good, the Bad and the Ugly, 3 NATURE
REVIEWS NEUROSCIENCE 302, 307-08 (2002).
271. See Yarkoni, supra note 134, at 494 box 3 (discussing how it could be more than a
decade before a fully automated quantitative brain map is clinically available).
272. Nuffort, supra note 11, at 10 (statement of Sen. Olympia Snowe).
273. Id.
274. NAT'L P'SHIP FOR WOMEN & FAMILIES,

FACES OF GENETIC DISCRIMINATION:

HOW

GENETIC DISCRIMINATION AFFECTS REAL PEOPLE 2 (2004) [hereinafter FACES], available at
http://www.nationalpartnership.org/site/DocServer/FacesofGeneticDiscrimination.pdf?docID=971
(quoting Sen. Thomas A. Daschle).
275. Id.
276. See Hamilton, supra note 10 (noting that it is important to somehow "grapple" with
these concerns now before the technologies become part of daily life); see also Jessica L. Roberts,
Preempting Discrimination: Lessons from the Genetic Information NondiscriminationAct, 63
VAND. L. REV. 439, 462 (2010) (discussing how GINA was enacted preemptively, with little
evidence indicating that there was actual discrimination taking place on a large scale at the
time).
277. Roberts, supra note 276, at 470.
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Consequently, despite differences in ease of access and in the
developmental stage of the underlying technologies, Title I of NINA
should parallel GINA Title II and prohibit employers from: (1)
requiring or requesting that employees or potential employees take a
neuroimaging test or provide neuro information as a condition of
employment; (2) using neuro information to discriminate against,
limit, segregate, or classify employees in a way that would deprive
them of employment opportunities; and (3) disclosing the neuro
information of employees after coming into possession of it.
B. Title II: Neuroenhancement and Employment Discrimination
GINA did not address the issue of genetic enhancement, most
likely because the methods of genetic enhancement are experimental,
are not FDA approved, and are prohibitively expensive. 278 In contrast,
in terms of the race toward enhancement, neuroscience is already
more advanced than genetics.2 79 Therefore, in order for federal
legislation to expansively prohibit employment discrimination on the
basis of neuroscience-based technology, it must incorporate an
additional section, not provided for in GINA, regarding explicit and
implicit discrimination on the basis of neuroenhancment.
NINA Title II should generally prohibit employers from
requesting or requiring that applicants and employees use
neuroenhancement techniques and from making employment
decisions based on such use or nonuse. Soldiers in the United States
have long been offered stimulant medication to enhance alertness,
including modafinil, 28 0 and are legally required to take medications if
ordered for the sake of their military performance. 28 ' Military
278. There are some ways available to genetically enhance humans, for example, through
gene therapy and prenatal diagnosis. In gene therapy, one gene is inserted into a genome to
replace another gene. U.S. Dep't of Energy Office of Sci., Gene Therapy, HUMAN GENOME
PROJECT INFORMATION, http://www.ornl.gov/sci/techresources/HumanGenome/medicine

genetherapy.shtml (last modified Aug. 24, 2011). Current gene therapy is experimental and has
not proven very successful in clinical trials. Id. The FDA has not yet approved any human gene
therapy product for sale. Id. Amniocentesis and preimplantation genetic diagnosis were
originally developed to detect serious genetic or chromosomal disorders. Green, supra note 182,
at 107. Some predict that as our ability to identify genetic bases of phenotypical traits grows, we
may eventually see parental requests to move in the direction of enhancement based on qualities
such as intelligence, height, and eye color. Id
279. See Green, supra note 182, at 107; discussion supra Part III (discussing the currently
available and utilized neuropharmaceuticals).
280. MORENO, supra note 114, at 114-16.
281. Henry Greely et al., Towards Responsible Use of Cognitive-EnhancingDrugs by the
Healthy, 456 NATURE 702, 703 (2008).
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physicians, citing the dangers of sleep-restricted environments, claim
an obligation to "help healthy individuals optimize their cognitive
potential."28 2 Presumably, the government has determined that the
safety benefits that the drug creates for the soldiers and those in
proximity to the soldiers in the context of serious military operations
outweigh any adverse side effects. 28 3 As Henry Greely, director of
Stanford's Center for Law and the Biosciences, points out, "For similar
reasons, namely the safety of the individual in question and others
who depend on that individual in dangerous situations, one could
imagine other occupations for which enhancement might be justifiably
required."28 4 Appropriate policy in NINA should accord to Greely's
directive and generally prohibit employers from requesting or
requiring employees to use neuroenhancement techniques, but should
allow for exceptions in specific circumstances where-due to the
specific occupation, the substantial gains in safety, and the safety of
the enhancement to its user-such enhancement is in society's best
interest.
Title II should also prohibit employers from indirectly
discriminating against applicants and employees on the basis of use or
nonuse of neuroenhancements. This issue is more "complex in that it
pits the rights of some potential employees to choose to enhance
against the rights of others to be free from the [implicit] coercive
pressure to enhance." 28 5 For example, if some commercial airline pilots
choose to engage in neuroenhancement and score higher on an
employer-administered performance-based test than those who choose
not to enhance, should an employer be prohibited from making
employment decisions based on the results of the test? Federal
legislation should aim at preserving this freedom of choice and
allowing employers to make employment decisions on the basis of
performance, but also should prevent employers from using the results
of performance-based tests as a pretext for discrimination.
Consideration should be given to the degree of enhancement, the
correlated ability for the performance-based test to detect the
enhancement, and the intent of the employer in administering such a
test.

282. Michael Russo et al., Letter to the Editor, Cosmetic Neurology: The Controversy Over
EnhancingMovement, Mentation, and Mood, 64 NEUROLOGY 1320, 1321 (2005).
283. Greely et al., supra note 281, at 703.
284. Id.
285. J.M. Appell, When the Boss Turns Pusher: A Proposal for Employee Protections in the
Age of Cosmetic Neurology, 34 J. MED. ETHICs 616, 617 (2008).
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CONCLUSION

Thomas Jefferson, one of this country's foremost political and
scientific leaders, wrote, "[L]aws and institutions must go hand in
hand with progress of the human mind. As . . . new discoveries are
made [and] new truths disclosed . . .institutions must advance also,
and keep pace with the times." 28 6 Brain information, like genetic
information, has the potential to yield great benefits as well as great
dangers. Due to the probabilistic predictive quality of both types of
data, concerns arise about ensuring that such information is not used
to unjustly deny employment. Furthermore, advancements in
neuropharmaceuticals create new risks of discrimination based on the
use or nonuse of enhancement techniques. GINA-like federal
legislation is essential to dispel such concerns and to protect
applicants and employees from neuroscience-based discrimination in
the workplace.
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